Amedeo Smart

Free Medical Literature Service


 

Amedeo

Otorhinolaryngology

  Free Subscription

Articles published in
Oral Oncol
    September 2022
  1. XUE F, Ou D, Ou X, Zhou X, et al
    Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2022;134:106139.
    >> Share

  2. SANKAR S
    New insights into CAR T-cell therapy for recurrent head and neck squamous cell carcinoma.
    Oral Oncol. 2022;134:106137.
    >> Share

  3. KMIECIK M, Nogal P, Wierzbicka M, Jackowska J, et al
    Anterolateral thigh free flap reconstruction of pharyngoesophageal defect caused by radiotherapy for laryngeal cancer: A case report.
    Oral Oncol. 2022;134:106135.
    >> Share

  4. GUPTA T, Kannan S, Ghosh-Laskar S, Agarwal JP, et al
    Concurrent chemoradiotherapy with cisplatin given once-a-week versus every-three weekly in head and neck squamous cell carcinoma: Non-inferior, equivalent, or superior?
    Oral Oncol. 2022;134:106130.
    >> Share

  5. HITT R, Mesia R, Lozano A, Iglesias Docampo L, et al
    Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
    Oral Oncol. 2022;134:106087.
    >> Share

  6. ZHANG J, Wu HY, Lu Q, Shan XF, et al
    Effects of personalized swallowing rehabilitation in patients with oral cancer after free flap transplantation: A cluster randomized controlled trial.
    Oral Oncol. 2022;134:106097.
    >> Share

  7. PATIL V, Kumar S, Noronha V, Menon N, et al
    Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.
    Oral Oncol. 2022;134:106085.
    >> Share

  8. SARODE GS, Anand R, Sharma NK, Sarode SC, et al
    Hot and cold tumor: Recent developments and perspectives on oral cancer.
    Oral Oncol. 2022;134:106114.
    >> Share

  9. BEOM HEO D, Piao Y, Hee Lee J, Ju SH, et al
    Completion thyroidectomy may not be required for papillary thyroid carcinoma with multifocality, lymphovascular invasion, extrathyroidal extension to the strap muscles, or five or more central lymph node micrometastasis.
    Oral Oncol. 2022;134:106115.
    >> Share

  10. SAHNI V, Kumar A, Gupta S, Sharma S, et al
    Metformin and oral cancer.
    Oral Oncol. 2022;134:106125.
    >> Share

  11. TOBIAS MAS, Nogueira BP, Santana MCS, Pires RG, et al
    Artificial intelligence for oral cancer diagnosis: What are the possibilities?
    Oral Oncol. 2022;134:106117.
    >> Share

  12. SHREE HARINI K, Ezhilarasan D, Elumalai P
    Restoring the anti-tumor property of PTEN: A promising oral cancer treatment.
    Oral Oncol. 2022;134:106113.
    >> Share

  13. NONG T, Medrano T, Marrero C, Rubens M, et al
    Radiation induced taste changes in head and neck cancer - differential impact of treatment factors.
    Oral Oncol. 2022;134:106105.
    >> Share

  14. MUTHUKRISHNAN L
    "TGM3 - A novel biomarker as a potential diagnostic target for head and neck squamous cell carcinoma (HNSCC)".
    Oral Oncol. 2022;134:106118.
    >> Share

  15. MONY U, Priya Veeraraghavan V
    "Rules" to the genetic progression of tumours deciphered: Is it time to think differently in treating oral cancer patients?
    Oral Oncol. 2022;134:106111.
    >> Share

  16. PRASAD M, Jayaraman S, Rajagopal P, Veeraraghavan VP, et al
    Apoptosis regulating CircRNAs: Emerging role in oral cancer therapeutics.
    Oral Oncol. 2022;134:106107.
    >> Share

  17. DE WIT JG, van Schaik JE, Voskuil FJ, Vonk J, et al
    Comparison of narrow band and fluorescence molecular imaging to improve intraoperative tumour margin assessment in oral cancer surgery.
    Oral Oncol. 2022;134:106099.
    >> Share

  18. VILASECA I, Xavier Aviles-Jurado F, Lehrer E, Valduvieco I, et al
    CO2-TOLMS for laryngeal cancer in the elderly, pushing the boundaries of partial laryngectomy.
    Oral Oncol. 2022;134:106088.
    >> Share

  19. YUAN H, Yan M, Liang X, Liu W, et al
    Decoding the associations between cell functional states in head and neck cancer based on single-cell transcriptome.
    Oral Oncol. 2022;134:106110.
    >> Share

  20. BALACHANDER K, Vijayashree Priyadharsini J, Paramasivam A
    Advances in oral cancer early diagnosis and treatment strategies with liquid biopsy-based approaches.
    Oral Oncol. 2022;134:106108.
    >> Share

  21. TAKENAKA Y, Takemoto N, Otsuka T, Nishio M, et al
    Predictive significance of body composition indices in patients with head and neck squamous cell carcinoma treated with nivolumab: A multicenter retrospective study.
    Oral Oncol. 2022;132:106018.
    >> Share

  22. CHABRILLAC E, Jackson R, Mattei P, D'Andrea G, et al
    Paratracheal lymph node dissection during total (pharyngo-)laryngectomy: A systematic review and meta-analysis.
    Oral Oncol. 2022;132:106017.
    >> Share

  23. DENG W, Zhao G, Li Z, Yang L, et al
    Recovery pattern analysis of swallowing function in patients undergoing total glossectomy and hemiglossectomy.
    Oral Oncol. 2022;132:105981.
    >> Share

    August 2022
  24. CHANDRALEKHA SELVAKUMAR S, Auxzilia Preethi K, Sekar D
    Non-coding RNAs influencing anti PD-1 immunotherapy in head and neck squamous cell carcinoma (HNSCC).
    Oral Oncol. 2022;134:106092.
    >> Share

  25. YADALAM PK, Anegundi RV, Ramadoss R, Joseph B, et al
    Felodipine repurposed for targeting TRPV1 receptor to relieve oral cancer pain.
    Oral Oncol. 2022;134:106094.
    >> Share

  26. SEMPRINI J
    Oral cancer screening prevalence in low-income adults before and after the ACA.
    Oral Oncol. 2022;134:106055.
    >> Share

  27. PAZHANI J, Veeraraghavan VP, Jayaraman S
    Aurora kinase in oral cancer: A potential therapeutic target to improve treatment efficiency.
    Oral Oncol. 2022;134:106093.
    >> Share

  28. KRUTZ M, Acharya P, Chissoe G, Raj V, et al
    Tobacco cessation after head and neck cancer diagnosis is an independent predictor of treatment response and long-term survival.
    Oral Oncol. 2022;134:106072.
    >> Share

  29. HEMPENIUS MA, Bisheshar SK, Slagter-Menkema L, van der Kamp MF, et al
    Inter-assay reliability of programmed cell death-ligand 1 in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;134:106086.
    >> Share

  30. VAISH R, Mittal N, Mahajan A, Rane SU, et al
    Sentinel node biopsy in node negative early oral cancers: Solution to the conundrum!
    Oral Oncol. 2022;134:106070.
    >> Share

  31. MUTHUPANDIAN S, Muralidharan M, Madhavan Y, Hariharan NM, et al
    Prospective role of salivary MicroRNA for early detection - personalized therapy of head and neck squamous cell carcinoma.
    Oral Oncol. 2022;134:106063.
    >> Share

  32. PARAMASIVAM A
    Circulating circular RNAs: Novel potential biomarkers and therapeutic targets for oral cancer.
    Oral Oncol. 2022;134:106067.
    >> Share

  33. EZHILARASAN D, Shree Harini K
    Novel mTOR inhibitors: Promising therapeutic interventions in oral cancer therapy.
    Oral Oncol. 2022;133:106066.
    >> Share

  34. PRASAD M, Veeraraghavan VP, Jayaraman S
    Tumorigenic potential of GLUT4: A therapeutic target for head and neck squamous cell carcinoma.
    Oral Oncol. 2022;133:106061.
    >> Share

  35. YU C, Zhou Z
    Relationship between young non-smokers and oral cancer: What can we learn?
    Oral Oncol. 2022;133:106064.
    >> Share

  36. REKHA K, Venkidasamy B, Govindasamy R, Neralla M, et al
    Isothiocyanates (AITC & BITC) bioactive molecules: Therapeutic potential for oral cancer.
    Oral Oncol. 2022;133:106060.
    >> Share

  37. BALACHANDER K, Abilasha R, Priyadharsini JV, Balamurugan R, et al
    Targeting mitochondria for apoptosis in oral cancer: Therapeutic potential and obstacles.
    Oral Oncol. 2022;133:106059.
    >> Share

  38. SARODE GS, Kumari N, Gophane R, Ghone U, et al
    Trends and prospects in oral cancer vaccine.
    Oral Oncol. 2022;133:106051.
    >> Share

  39. MA SJ, Yu H, Khan M, Yu B, et al
    Defining the optimal threshold and prognostic utility of pre-treatment hemoglobin level as a biomarker for survival outcomes in head and neck cancer patients receiving chemoradiation.
    Oral Oncol. 2022;133:106054.
    >> Share

  40. VERDONCK-DE LEEUW I, Dawson C, Licitra L, Eriksen JG, et al
    European Head and Neck Society recommendations for head and neck cancer survivorship care.
    Oral Oncol. 2022;133:106047.
    >> Share

  41. DONA MG, Rollo F, Pichi B, Moretto S, et al
    Updates on Human Papillomavirus-driven oropharyngeal squamous cell carcinomas in a southern European country.
    Oral Oncol. 2022;131:105947.
    >> Share

    July 2022
  42. DASSE R, Dupin C, Gorphe P, Temam S, et al
    Proposal for an algorithm to avoid neck dissection during salvage total laryngectomy. A GETTEC multicentric study.
    Oral Oncol. 2022;133:106026.
    >> Share

  43. CHOW JCH, Lee AWM, Wong CHL, Ng WT, et al
    Epstein-Barr virus directed screening for nasopharyngeal carcinoma in individuals with positive family history: A systematic review.
    Oral Oncol. 2022;133:106031.
    >> Share

  44. KRISHNAN M, Venkidasamy B
    PEITC: A prospective natural metabolite in oral cancer treatment.
    Oral Oncol. 2022;133:106044.
    >> Share

  45. YU C, Zhou Z
    Assessment of oral dysfunction after oral cancer treatment.
    Oral Oncol. 2022;133:106046.
    >> Share

  46. SARODE GS, Sarode SC, Kumari N, Gophane R, et al
    FAP-targeted imaging in oral cancer: Critical viewpoints.
    Oral Oncol. 2022;133:106024.
    >> Share

  47. YASASVE M, Manjusha M, Saravanan M
    Polymorphism in pro-inflammatory cytokines and their genetic susceptibility towards oral precancerous lesions and oral cancer.
    Oral Oncol. 2022;133:106027.
    >> Share

  48. KONO M, Saito S, Egloff AM, Allen CT, et al
    The mouse oral carcinoma (MOC) model: A 10-year retrospective on model development and head and neck cancer investigations.
    Oral Oncol. 2022;132:106012.
    >> Share

  49. MELO G, Silva CAB, Hague A, Parkinson EK, et al
    Anticancer effects of putative and validated BH3-mimetic drugs in head and neck squamous cell carcinomas: An overview of current knowledge.
    Oral Oncol. 2022;132:105979.
    >> Share

  50. KUMARESAN V, Sivaperumal P, Smiline Girija AS
    Bispecific antibodies targeting tumor-associated metalloprotease and recruit NK cells - Multifunctional therapeutic approach against oral cancer.
    Oral Oncol. 2022;132:106013.
    >> Share

  51. HUANG H, Li L, Cao Q, Jiang H, et al
    Choroid plexus papilloma of auditory nerve: A case report.
    Oral Oncol. 2022;132:106009.
    >> Share

  52. RENU K, Veeraraghavan VP, Raj A T, Patil S, et al
    The peroxisome proliferator-activated receptor-alpha (PPAR-alpha): A new therapeutic target for oral cancer.
    Oral Oncol. 2022;132:106007.
    >> Share

  53. ALLEN JL, Hames RA, Mastroianni NM, Greenstein AE, et al
    Evaluation of the matrix metalloproteinase 9 (MMP9) inhibitor Andecaliximab as an Anti-invasive therapeutic in Head and neck squamous cell carcinoma.
    Oral Oncol. 2022;132:106008.
    >> Share

  54. SARODE GS, Kumari N, Sarode SC
    Oral cancer histopathology images and artificial intelligence: A pathologist's perspective.
    Oral Oncol. 2022;132:105999.
    >> Share

  55. DE VRIES J, Poelman A, Sidorenkov G, Festen S, et al
    The association of frailty and outcomes of geriatric assessment with acute radiation-induced toxicity in patients with head and neck cancer.
    Oral Oncol. 2022;130:105933.
    >> Share

  56. RIBEIRO MFA, Oliveira MCM, Leite AC, Bruzinga FFB, et al
    Assessment of screening programs as a strategy for early detection of oral cancer: a systematic review.
    Oral Oncol. 2022;130:105936.
    >> Share

  57. TANG R, Mao S, Liu S, Li Z, et al
    Types of endoscopic surgical approaches for benign parapharyngeal space tumors.
    Oral Oncol. 2022;130:105875.
    >> Share

  58. EZHILARASAN D, Shree Harini K, Lakshmi T
    Osteopontin: A reliable diagnostic marker and an attractive therapeutic target in oral cancers.
    Oral Oncol. 2022;132:106005.
    >> Share

    June 2022
  59. MISRA SR, Das R
    Central oral medicine repository: A proposal to speed up the diagnostic process for oral potentially malignant disorders and oral carcinoma!
    Oral Oncol. 2022;132:105998.
    >> Share

  60. BALACHANDER K, Paramasivam A
    Anti-PD-1 agent: A promising immunotherapy drug for oral cancer?
    Oral Oncol. 2022;132:105997.
    >> Share

  61. BABU S, Krishnan M, Priya Veeraraghavan V, Jayaraman S, et al
    Role of salivary miRNAs in the diagnosis and prognosis of head and neck squamous cell carcinoma.
    Oral Oncol. 2022;132:105993.
    >> Share

  62. ALESSANDRINI L, Ferrari M, Taboni S, Sbaraglia M, et al
    Tumor-stroma ratio, neoangiogenesis and prognosis in laryngeal carcinoma. A pilot study on preoperative biopsies and matched surgical specimens.
    Oral Oncol. 2022;132:105982.
    >> Share

  63. SHREE HARINI K, Ezhilarasan D, Lakshmi T
    Novel fibroblast growth factor receptor inhibitors: Potential therapeutic approach in oral cancer treatment.
    Oral Oncol. 2022;132:105983.
    >> Share

  64. REVATHI D, Dhanraj G, Ashok V
    Immune check point inhibitors: A promising therapeutic approach in oral cancer.
    Oral Oncol. 2022;132:105977.
    >> Share

  65. SEKARAN S, Pitchaiah S, Ganapathy D
    Can miR-21 be considered as a potential biomarker and a therapeutic target in oral cancer?
    Oral Oncol. 2022;131:105973.
    >> Share

  66. ZONG J, Ji P, Lin C, Zhang R, et al
    Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma.
    Oral Oncol. 2022;131:105972.
    >> Share

  67. BALACHANDER K, Paramasivam A
    Ferroptosis: An emerging therapeutic target for oral cancer.
    Oral Oncol. 2022;131:105970.
    >> Share

  68. GANAPATHY D, Sekaran S, Pitchaiah S
    Is prognostic monitoring of high-risk populations at risk for oral cancer necessary after infection with COVID-19?
    Oral Oncol. 2022;131:105968.
    >> Share

  69. LUO HD, Xia FJ, Wu JH, Yi B, et al
    Efficacy of chemoradiotherapy in survival of stage nasopharyngeal carcinoma and establishment of a prognostic model.
    Oral Oncol. 2022;131:105927.
    >> Share

  70. SHREE HARINI K, Ezhilarasan D, Lakshmi T
    Patient derived tumour organoids: An emerging strategy in oral cancer research and therapeutics.
    Oral Oncol. 2022;131:105954.
    >> Share

  71. VARGHESE BT, Nair SP, Janardhan D
    Transglottic intralaryngeal papillary thyroid carcinoma.
    Oral Oncol. 2022;131:105935.
    >> Share

  72. YANG Z, Liao J, Schumaker L, Carter-Cooper B, et al
    Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.
    Oral Oncol. 2022;131:105939.
    >> Share

  73. SHREE HARINI K, Ezhilarasan D
    Promising autophagy inhibitors: Therapeutic implications in oral cancer.
    Oral Oncol. 2022;131:105948.
    >> Share

  74. DE FELICE F
    FLASH radiotherapy in head and neck cancer: Myth or reality?
    Oral Oncol. 2022;131:105953.
    >> Share

  75. FERRELI F, Pirola F, Di Santo D, De Virgilio A, et al
    A critical analysis of the classifications of squamous cell carcinoma of the nasal vestibule.
    Oral Oncol. 2022;129:105880.
    >> Share

    May 2022
  76. JAYARAMAN S, Pazhani J, PriyaVeeraraghavan V, Raj AT, et al
    PCNA and Ki67: Prognostic proliferation markers for oral cancer.
    Oral Oncol. 2022;130:105943.
    >> Share

  77. BALACHANDER K, Paramasivam A
    Selective autophagy as a potential therapeutic target for oral cancer.
    Oral Oncol. 2022;130:105934.
    >> Share

  78. PATIL VM, Kolkur M, Kumar Chinthala S, Waratkar G, et al
    Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients.
    Oral Oncol. 2022;130:105908.
    >> Share

  79. UEDA Y, Okano S, Enokida T, Fujisawa T, et al
    Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study.
    Oral Oncol. 2022;130:105932.
    >> Share

  80. WARNER L, O'Hara JT, Lin DJ, Oozeer N, et al
    Transoral robotic surgery and neck dissection alone for head and neck squamous cell carcinoma: Influence of resection margins on oncological outcomes.
    Oral Oncol. 2022;130:105909.
    >> Share

  81. VARGHESE BT, Shivanesan P
    Anatomical distortion of the right recurrent laryngeal nerve in level 7 neck dissection.
    Oral Oncol. 2022;130:105929.
    >> Share

  82. SMILINE GIRIJA AS
    Natural "epidrugs" and the need of basket trials in the treatment of oral cancer in India.
    Oral Oncol. 2022;130:105931.
    >> Share

  83. SHIAO JC, Holt D, Ladbury C, Gao D, et al
    The role of concomitant chemoradiotherapy versus radiation alone in T1-3N0 HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;130:105907.
    >> Share

  84. LOW SK, Reed CT, Millo C, Turkbey EB, et al
    Cecal mass: An unusual site of metastasis from HPV-associated oropharyngeal cancer.
    Oral Oncol. 2022;130:105928.
    >> Share

  85. PARAMASIVAM A
    Plasma circulating tumor DNA as a molecular marker for oral cancer.
    Oral Oncol. 2022;130:105926.
    >> Share

  86. SELVARAJ J, Yasothkumar D, Vishnu Priya V, Raj AT, et al
    Development and tumorigenic potential of TP53: A therapeutic target for head and neck squamous cell carcinoma.
    Oral Oncol. 2022;130:105922.
    >> Share

  87. YANG X, Song H, Ji T, Du G, et al
    The implications of gene mutations in salivary DNA for noninvasive diagnosis of head and neck cancer with a focus on oral cancer.
    Oral Oncol. 2022;130:105924.
    >> Share

  88. FORNER D, Mok F, Verma N, Karam I, et al
    Placement technique impacts gastrostomy tube-related complications amongst head and neck cancer patients.
    Oral Oncol. 2022;130:105903.
    >> Share

  89. PAZHANI J, Jayaraman S, Veeraraghavan VP, Somasundaram DB, et al
    Targeting cancer associated fibroblasts - A TGF-beta based immunotherapy for head and neck squamous cell carcinoma.
    Oral Oncol. 2022;130:105899.
    >> Share

  90. JIANG Y, Yang S, Qi Y
    Comment on: The prognostic value of radiologic extranodal extension in nasopharyngeal carcinoma: Systematic review and meta-analysis.
    Oral Oncol. 2022;130:105872.
    >> Share

  91. MADY LJ, Baddour K, Hodges JC, Magana LC, et al
    Corrigendum to "The impact of frailty on mortality in non-surgical head and neck cancer treatment: Shifting the clinical paradigm" [Oral Oncol. 126 (2022) 105766].
    Oral Oncol. 2022 May 2:105882. doi: 10.1016/j.oraloncology.2022.105882.
    >> Share

  92. SWARTZ JE, Smits HJG, Philippens MEP, de Bree R, et al
    Correlation and colocalization of HIF-1alpha and pimonidazole staining for hypoxia in laryngeal squamous cell carcinomas: A digital, single-cell-based analysis.
    Oral Oncol. 2022;128:105862.
    >> Share

  93. YEOM S, Jung EK, Lee DH, Lee JK, et al
    Clinical features and recurrence factors of benign neoplasms of the tongue base.
    Oral Oncol. 2022;128:105866.
    >> Share

  94. MULLER RG, Hamill CS, Vu B, Thuener J, et al
    Impact of AJCC 8th edition staging system and definitive treatment choice on the prognosis of complete responders with p16+ and p16- oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2022;128:105861.
    >> Share

    April 2022
  95. GALLOGLY JA JR, Weber AK, Mazul AL, Brinkmeier JV, et al
    Inferior outcomes associated with emergency department presentation for head and neck cancer surgery.
    Oral Oncol. 2022;129:105894.
    >> Share

  96. SHE L, Tian K, Han J, Zuo W, et al
    Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis.
    Oral Oncol. 2022;129:105871.
    >> Share

  97. KATO A, Matsuda Y, Morioka R, Okui T, et al
    Discrepancy between subjective and objective postoperative oral dysfunction assessment after oral cancer treatment: A single-center cross-sectional study.
    Oral Oncol. 2022;129:105879.
    >> Share

  98. HAIST C, Poschinski Z, Bister A, Hoffmann MJ, et al
    Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas.
    Oral Oncol. 2022;129:105867.
    >> Share

  99. SEKAR D, Panagal M, Manimaran D, Ahmad N, et al
    miR-185 and its anti-miR as a biomarker and therapeutic target for oral cancer.
    Oral Oncol. 2022;129:105873.
    >> Share

  100. LIU T, Ma L, Song L, Yan B, et al
    CENPM upregulation by E5 oncoprotein of human papillomavirus promotes radiosensitivity in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;129:105858.
    >> Share

  101. NERALLA M, Senthilnthan P, Kubendiran D, Nandan A, et al
    Dry needle therapy for post operative shoulder dysfunction in oral cancer patients.
    Oral Oncol. 2022;128:105865.
    >> Share

  102. PETRELLI F, Trevisan F, Ghidini A, Capriotti V, et al
    Comparison of platinum-based regimens in combination with radiotherapy for head and neck cancers: A network meta-analysis.
    Oral Oncol. 2022;128:105864.
    >> Share

  103. ZHOU S, Chan C, Rulach R, Dyab H, et al
    Long term survival in patients with human papillomavirus-positive oropharyngeal cancer and equivocal response on 12-week PET-CT is not compromised by the omission of neck dissection.
    Oral Oncol. 2022;128:105870.
    >> Share

  104. YANG ZC, Nie ZQ, Chen QY, Du CC, et al
    Cost-Effectiveness analysis of combining plasma Epstein-Barr virus DNA testing and different surveillance imaging modalities for nasopharyngeal carcinoma patients in first remission.
    Oral Oncol. 2022;128:105851.
    >> Share

  105. FENG G, Feng H, Qi Y, Wang T, et al
    Interaction analysis between germline genetic variants and somatic mutations in head and neck cancer.
    Oral Oncol. 2022;128:105859.
    >> Share

  106. CHEN Y, Zheng X, Lin J, Gao X, et al
    A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
    Oral Oncol. 2022;128:105860.
    >> Share

  107. TIAN K, Han J, Wang Z, Chen J, et al
    Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis.
    Oral Oncol. 2022;128:105842.
    >> Share

  108. BALACHANDER K, Roy A, Priyadharsini JV, Murugan S, et al
    Mitochondrial DNA in circulating exosomes: A novel biomarker and potential therapeutic target for oral cancer.
    Oral Oncol. 2022;128:105857.
    >> Share

  109. DE LA COUR CD, Munk C, Aalborg GL, Kjaer SK, et al
    Base of tongue/tonsillar and laryngeal cancer in Denmark 1994-2018: Temporal trends in incidence according to education and age.
    Oral Oncol. 2022;128:105832.
    >> Share

  110. BANERJEE A, Misra SR, Roy B, Singh S, et al
    Central oral histopathology registry (COHR) - A proposal promising hope for oral cancer and oral pathology research.
    Oral Oncol. 2022;128:105856.
    >> Share

  111. SEKAR D, Murthykumar K, Ganapathy D
    miR-206 and its mimics: A predictive biomarker and therapeutic molecule in the treatment of oral cancer.
    Oral Oncol. 2022;128:105849.
    >> Share

  112. RISCHIN D, Harrington KJ, Greil R, Soulieres D, et al
    Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
    Oral Oncol. 2022;128:105815.
    >> Share

  113. TANS L, Al-Mamgani A, Kwa SLS, Elbers JBW, et al
    Single vocal cord irradiation for early-stage glottic cancer: Excellent local control and favorable toxicity profile.
    Oral Oncol. 2022;127:105782.
    >> Share

  114. DODDAWAD VG, Premalatha BR, Sreeshyla HS, Nitin P, et al
    Classification staging systems on clinical and radiographic features of inverted sinonasal papilloma: A case report.
    Oral Oncol. 2022;127:105768.
    >> Share

    March 2022
  115. PATIL V, Noronha V, Joshi A, Menon N, et al
    RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation.
    Oral Oncol. 2022;128:105816.
    >> Share

  116. CHANG CT, Liu SP, Muo CH, Liao YF, et al
    The impact of dental therapy timelines and irradiation dosages on osteoradionecrosis in oral cancer patients: A population-based cohort study.
    Oral Oncol. 2022;128:105827.
    >> Share

  117. HSIEH MC, Wang CC, Yang CC, Lien CF, et al
    The role of induction chemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A nationwide population-based matched study.
    Oral Oncol. 2022;128:105848.
    >> Share

  118. YANG X, Xu X, Zhang C, Ji T, et al
    The diagnostic value and prospects of gene mutations in circulating tumor DNA for head and neck cancer monitoring.
    Oral Oncol. 2022;128:105846.
    >> Share

  119. RANJAN MISRA S, Das R
    Tele-screening for early detection of oral cancer during the COVID-19 pandemic era: Diagnostic pitfalls and potential misinterpretations!
    Oral Oncol. 2022;128:105845.
    >> Share

  120. MATTOX AK, D'Souza G, Khan Z, Allen H, et al
    Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer.
    Oral Oncol. 2022;128:105805.
    >> Share

  121. BALACHANDER K, Paramasivam A
    Cell-free mitochondrial DNA as a novel non-invasive biomarker for oral cancer.
    Oral Oncol. 2022;127:105825.
    >> Share

  122. YAMAGUMA Y, Kaneuji T, Shirouzu S, Fukui T, et al
    Combination therapy of Mohs paste and chemotherapy improved metastatic oral cancer to the precordium skin and bilateral axillary lymph nodes: A case report.
    Oral Oncol. 2022;127:105817.
    >> Share

  123. VILLARD A, Breuskin I, Casiraghi O, Asmandar S, et al
    Confocal laser endomicroscopy and confocal microscopy for head and neck cancer imaging: Recent updates and future perspectives.
    Oral Oncol. 2022;127:105826.
    >> Share

  124. PATIL V, Alone M, Rai R, Noronha V, et al
    Safety and efficacy of pembrolizumab with chemotherapy in locally advanced head and neck cancers.
    Oral Oncol. 2022;127:105824.
    >> Share

  125. DE LUCA P, Di Stadio A, Tassone D, de Campora L, et al
    Large cervical mass and head and neck cancer. First report of ectopic papillary adenoma of the lung.
    Oral Oncol. 2022;127:105823.
    >> Share

  126. DEVARAJA K, Kabekkodu SP
    Oral microbiome; a potential game-changer in the management of oral cancer?
    Oral Oncol. 2022;127:105822.
    >> Share

  127. BONETTI VALENTE V, Mantovan Mazzon B, Urbano Collado F, Conrado Neto S, et al
    Clinicopathological and prognostic profile of non-smoking and non-drinking head and neck cancer patients: a population-based comparative study.
    Oral Oncol. 2022;127:105799.
    >> Share

  128. SHETH S, Gilbert J, Deal AM, Chera B, et al
    Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105807.
    >> Share

  129. VALERO C, Yuan A, Zanoni DK, Lei E, et al
    Young non-smokers with oral cancer: What are we missing and why?
    Oral Oncol. 2022;127:105803.
    >> Share

  130. ELUMALAI P, Ezhilarasan D, Lakshmi T
    Targeting head and neck cancer epigenetics with CRISPR-dCas9: An emerging therapeutic approach.
    Oral Oncol. 2022;127:105801.
    >> Share

  131. GLAZAR DJ, Johnson M, Farinhas J, Steuer CE, et al
    Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab.
    Oral Oncol. 2022;127:105787.
    >> Share

  132. ROUTILA J, Qiao X, Weltner J, Rantala JK, et al
    Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105772.
    >> Share

  133. BRODY RM, Shimunov D, Cohen RB, Lin A, et al
    A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers.
    Oral Oncol. 2022;127:105798.
    >> Share

  134. GONCALVES JM, Scarini JF, Gondak R, Altemani A, et al
    Oral involvement of sinonasal undifferentiated carcinoma: A case report and immunohistochemical study of a challenging case.
    Oral Oncol. 2022;126:105779.
    >> Share

  135. SAKTHIVEL P, Raveendran S, Rajeshwari M
    Sinonasal small round blue cell tumors: What the clinician must know!
    Oral Oncol. 2022;126:105735.
    >> Share

  136. PETRIDES GA, Dunn M, Charters E, Venchiarutti R, et al
    Health-related quality of life in maxillectomy patients undergoing dentoalveolar rehabilitation.
    Oral Oncol. 2022;126:105757.
    >> Share

    February 2022
  137. QURESHI HA, Zhu X, Yang GH, Steadele M, et al
    Impact of HPV status on immune responses in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105774.
    >> Share

  138. BELGIOIA L, Becherini C, Bacigalupo A, Bonomo P, et al
    Chemo- immunotherapy and radiation in locally advanced head and neck cancer: Where do we stand?
    Oral Oncol. 2022;127:105773.
    >> Share

  139. DAGLINAMRATA, Lakshmi T, Rushabh D, Dineshkumar T, et al
    Telescreening as an alternate modality for early detection of oral cancer.
    Oral Oncol. 2022;127:105785.
    >> Share

  140. HARING CT, Dermody SM, Yalamanchi P, Kang SY, et al
    The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;126:105776.
    >> Share

  141. MICHMERHUIZEN NL, Heenan C, Wang J, Leonard E, et al
    Combined Pik3ca-H1047R and loss-of-function Notch1 alleles decrease survival time in a 4-nitroquinoline N-oxide-driven head and neck squamous cell carcinoma model.
    Oral Oncol. 2022;126:105770.
    >> Share

  142. MADY LJ, Baddour K, Hodges JC, Magana LC, et al
    The impact of frailty on mortality in non-surgical head and neck cancer treatment: Shifting the clinical paradigm.
    Oral Oncol. 2022;126:105766.
    >> Share

  143. ZHANG S, Zhang W, Zhang J
    Comprehensive analysis of immune cell infiltration and significant genes in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;126:105755.
    >> Share

  144. LI JL, Hsieh TL, Ou MC, Lin FC, et al
    Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio during immune checkpoint inhibitor treatment in recurrent or metastatic head and neck squamous cell carcinoma patients.
    Oral Oncol. 2022;126:105729.
    >> Share

  145. LENOCI D, Carenzo A, Cavalieri S, Pistore F, et al
    Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials.
    Oral Oncol. 2022;126:105756.
    >> Share

  146. CHAN SK, Lin C, Huang SH, Chau TC, et al
    Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2022;126:105736.
    >> Share

  147. SILVERMAN DA, Parikh AS, Liu K, Zhan KY, et al
    Predictors of survival following carotid blowout syndrome.
    Oral Oncol. 2022;125:105723.
    >> Share

  148. CHIN O, Alshafai L, O'Sullivan B, Su J, et al
    Inter-rater concordance and operating definitions of radiologic nodal feature assessment in human papillomavirus-positive oropharyngeal carcinoma.
    Oral Oncol. 2022;125:105716.
    >> Share

  149. CHEN TC, Wang C, Su LY, Lin MC, et al
    Impact of invasion into cervical esophagus for patients with hypopharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;125:105683.
    >> Share

    January 2022
  150. SENGUPTA N, Sarode SC, Sarode GS, Ghone U, et al
    Scarcity of publicly available oral cancer image datasets for machine learning research.
    Oral Oncol. 2022;126:105737.
    >> Share

  151. JONAS H, Simnica D, Bussmann L, Zech H, et al
    Early relapse detection by monitoring of circulating cell-free DNA in patients with localized head and neck squamous cell carcinoma: A subgroup analysis of the multicenter randomized clinical trial IMSTAR-HN.
    Oral Oncol. 2022;126:105733.
    >> Share

  152. SEKAR D
    Inhibition of OSCC derived ExomiRs and its therapeutic applications in oral cancer.
    Oral Oncol. 2022;126:105747.
    >> Share

  153. FERRAZZO KL
    Regarding: "Clinical practice guidelines for dental management prior to radiation for head and neck cancer".
    Oral Oncol. 2022;126:105731.
    >> Share

  154. WARD MC, Miller JA, Walker GV, Moeller BJ, et al
    The economic impact of circulating tumor-tissue modified HPV DNA for the post-treatment surveillance of HPV-driven oropharyngeal cancer: A simulation.
    Oral Oncol. 2022;126:105721.
    >> Share

  155. LIU X, Li WF, Ding C, Chen L, et al
    Differential benefit of induction chemotherapy according to body mass index in nasopharyngeal carcinoma - Pooled analysis of two randomized trials.
    Oral Oncol. 2022;125:105718.
    >> Share

  156. K AP, Selvakumar SC, Selvaraj J, Mony U, et al
    Reviewing the potential application of miR-21 inhibitors in oral cancer therapeutics.
    Oral Oncol. 2022;125:105713.
    >> Share

  157. ECONOMOPOULOU P, Kotsantis I, Psyrri A
    Radiotherapy and immunotherapy combination in head and neck cancer: Does current failure qualify as an ending or is it a key to future success?
    Oral Oncol. 2022 Jan 13:105717. doi: 10.1016/j.oraloncology.2022.105717.
    >> Share

  158. CARDIN GB, Bernard M, Bourbonnais J, Bahig H, et al
    The rs6942067 genotype is associated with a worse overall survival in young or non-smoking HPV-negative patients with positive nodal status in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;125:105696.
    >> Share

  159. GILLIGAN G, Piemonte E, Lazos J, Panico R, et al
    Chronic wounds of traumatic origin and oral cancer arising de novo: A potential association?
    Oral Oncol. 2022;125:105711.
    >> Share

  160. PATIL V, Ghandade N, Noronha V, Menon N, et al
    Hypomagnesemia in patients with locally advanced head and neck cancer treated weekly cisplatin-incidence and impact on outcomes.
    Oral Oncol. 2022;125:105709.
    >> Share

  161. VIITASALO S, Karhemo PR, Vaananen J, Ilmarinen T, et al
    Exome sequencing reveals candidate mutations implicated in sinonasal carcinoma and malignant transformation of sinonasal inverted papilloma.
    Oral Oncol. 2022;124:105663.
    >> Share

  162. SAKTHIVEL P, Thakar A, Fernandez-Fernandez MM, Panda S, et al
    TransOral UltraSonic surgery (TOUSS) for oral cavity, oropharyngeal and supraglottic malignancy: A prospective study of feasibility, safety, margins, functional and survival outcomes.
    Oral Oncol. 2022;124:105643.
    >> Share

  163. LI MM, Mroz EA, Faquin WC, Lott-Limbach A, et al
    ERalpha: A biomarker and treatment target for oropharyngeal cancer?
    Oral Oncol. 2022;124:105637.
    >> Share

  164. MALIK A, Panda S, Sakthivel P
    Treatment of early glottic carcinoma: Is it a paradox of choices?
    Oral Oncol. 2022;124:105516.
    >> Share

  165. ZHANG L, Chen L, Xiao M, Xie X, et al
    Locally advanced undifferentiated sarcomatoid carcinoma of the right maxillary sinus with PDCD6-TERT fusion: A rare case report.
    Oral Oncol. 2022;124:105466.
    >> Share

    December 2021
  166. COHEN O, Brauer PR, Judson BL, Burtness BA, et al
    Guideline - Adherence in advanced stage head and neck cancer is associated with improved survival - A National study.
    Oral Oncol. 2021;125:105694.
    >> Share

  167. WANG J, Tian Y, Huang H, Huang D, et al
    The prognosis of HPV-associated metastatic pharyngeal patients by primary and distant site.
    Oral Oncol. 2021;125:105675.
    >> Share

  168. SUBASH A, Bylapudi B, Thakur S, Rao VUS, et al
    Oral cancer in India, a growing problem: Is limiting the exposure to avoidable risk factors the only way to reduce the disease burden?
    Oral Oncol. 2021;125:105677.
    >> Share

  169. MERCHANT YP, Mohan M, Shetty S, Bandemegal M, et al
    The submandibular gland in neck dissection: A necessary casualty or a hapless victim?
    Oral Oncol. 2021;125:105678.
    >> Share

  170. HERNDON P, Jassal JS, Cramer JD
    Association between E-cigarette use and oral HPV-16 infection.
    Oral Oncol. 2021;125:105676.
    >> Share

  171. DOU Y, Ma C, Wang K, Liu S, et al
    Dysbiotic tumor microbiota associates with head and neck squamous cell carcinoma outcomes.
    Oral Oncol. 2021;124:105657.
    >> Share

  172. NOJI R, Kano Y, Hirai H, Onishi I, et al
    MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma.
    Oral Oncol. 2021;124:105666.
    >> Share

  173. WEI LY, Lin HC, Tsai FC, Ko JY, et al
    Effects of Interleukin-6 on STAT3-regulated signaling in oral cancer and as a prognosticator of patient survival.
    Oral Oncol. 2021;124:105665.
    >> Share

  174. SARI SY, Yilmaz MT, Aktas BY, Aksoy S, et al
    Results of concurrent radiotherapy and immunotherapy in recurrent and metastatic head and neck cancer: A single-center experience.
    Oral Oncol. 2021;124:105658.
    >> Share

  175. CRAMER JD, Grauer J
    Modeling oral cancer screening in the United States population.
    Oral Oncol. 2021;124:105656.
    >> Share

  176. BIGELOW EO, Windon MJ, Fakhry C, Kiess AP, et al
    Development of a web-based, patient-centered decision aid for oropharyngeal cancer treatment.
    Oral Oncol. 2021;123:105618.
    >> Share

  177. BURNINGHAM K, Moore W, Moon D, Avkshtol V, et al
    Prognostic impact of matted lymphadenopathy in patients with oropharyngeal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Oral Oncol. 2021;123:105623.
    >> Share

    November 2021
  178. GUPTA T, Maheshwari G, Kannan S, Nair S, et al
    Systematic review and meta-analysis of randomized controlled trials comparing elective neck dissection versus sentinel lymph node biopsy in early-stage clinically node-negative oral and/or oropharyngeal squamous cell carcinoma: Evidence-base for pract
    Oral Oncol. 2021;124:105642.
    >> Share

  179. CHAUHAN A, Kaur R, Ghoshal S, Chatterjee D, et al
    Potential prognostic and predictive role of baseline circulating tumor cells in head and neck squamous cell carcinoma.
    Oral Oncol. 2021;124:105636.
    >> Share

  180. FUEREDER T, Minichsdorfer C, Mittlboeck M, Wagner C, et al
    Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study.
    Oral Oncol. 2021;124:105634.
    >> Share

  181. DENARO N, Merlano M, Garrone O
    In reply to immune desert in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
    Oral Oncol. 2021;124:105640.
    >> Share

  182. THADURI A, Dungala D, Panuganti A, Majumdar KS, et al
    Addressing the challenges of head and neck cancer care in India - A compelling need of the hour.
    Oral Oncol. 2021;124:105638.
    >> Share

  183. MADHULAXMI M, Abhinav RP
    Protein changes of WNT signaling pathway in oral cancer.
    Oral Oncol. 2021;123:105624.
    >> Share

  184. KOWALCHUK RO, Van Abel KM, Yin LX, Garcia J, et al
    Correlation between radiographic and pathologic lymph node involvement and extranodal extension via CT and PET in HPV-associated oropharyngeal cancer.
    Oral Oncol. 2021;123:105625.
    >> Share

  185. GAU M, Fonseca A, Ozsahin M, Fayette J, et al
    Prognostic impact of extranodal extension in resected head and neck squamous cell carcinomas in the era of postoperative chemoradiation: A retrospective monocentric study.
    Oral Oncol. 2021;123:105605.
    >> Share

  186. MISHRA S, Subash A, Rao VUS, Thakur S, et al
    Role of neoadjuvant chemotherapy in head and neck cancer management: A case for exploring diverse treatment strategies for evaluating long-term efficacy.
    Oral Oncol. 2021;123:105594.
    >> Share

  187. GOLUSINSKI P, Corry J, Poorten VV, Simo R, et al
    De-escalation studies in HPV-positive oropharyngeal cancer: How should we proceed?
    Oral Oncol. 2021;123:105620.
    >> Share

  188. WATSON E, Dorna Mojdami Z, Oladega A, Hope A, et al
    Clinical practice guidelines for dental management prior to radiation for head and neck cancer.
    Oral Oncol. 2021;123:105604.
    >> Share

  189. BRIL SI, Chargi N, Wendrich AW, Wegner I, et al
    Validation of skeletal muscle mass assessment at the level of the third cervical vertebra in patients with head and neck cancer.
    Oral Oncol. 2021;123:105617.
    >> Share

  190. WANG Y, Gao Y, Yuan L, Zhang J, et al
    Psychological needs and associated factors among perioperative patients with oral cancer.
    Oral Oncol. 2021;123:105615.
    >> Share

  191. GRONLUND MP, Jakobsen KK, Mirian C, Gronhoj C, et al
    Nasopharyngeal malignancies in Denmark diagnosed from 1980 to 2014.
    Oral Oncol. 2021;122:105583.
    >> Share

  192. YU J, Tsay C, Sasaki C, Son YH, et al
    Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs.
    Oral Oncol. 2021;122:105585.
    >> Share

  193. SEE A, Chu C, Kiong KL, Teo C, et al
    Surgical salvage of recurrent nasopharyngeal cancer- a multi-institutional review.
    Oral Oncol. 2021;122:105556.
    >> Share

  194. SAKTHIVEL P, Ramanikanth TV, Thakar A, Singh CA, et al
    TransOral UltraSonic Surgery (TOUSS) assisted supraglottic laryngectomy: Expanding the spectrum of endoscopic head and neck surgeries.
    Oral Oncol. 2021;122:105562.
    >> Share

  195. THAKAR A, Sakthivel P, Sikka K
    TransOral UltraSonic Surgery (TOUSS) and TransOral Laser (TOL) assisted supraglottic laryngectomy (TOUSS-TOL-SGL): Improvising techniques within the transoral corridor.
    Oral Oncol. 2021;122:105573.
    >> Share

  196. LIN N, Gao J, Wang H, Zhang H, et al
    Diagnostic value of indocyanine green for sentinel lymph node mapping and lymph node metastasis in oral/oropharyngeal carcinoma.
    Oral Oncol. 2021;122:105563.
    >> Share

  197. RE M, Tomasetti M, Monaco F, Amati M, et al
    NGS-based miRNome identifies miR-449 cluster as marker of malignant transformation of sinonasal inverted papilloma.
    Oral Oncol. 2021;122:105554.
    >> Share

  198. MCDOWELL L, Casswell G, Bressel M, Drosdowsky A, et al
    Symptom burden, quality of life, functioning and emotional distress in survivors of human papillomavirus associated oropharyngeal cancer: An Australian cohort.
    Oral Oncol. 2021;122:105560.
    >> Share

  199. MIN PARK Y, Yol Lim J, Woo Koh Y, Kim SH, et al
    Prediction of treatment outcome using MRI radiomics and machine learning in oropharyngeal cancer patients after surgical treatment.
    Oral Oncol. 2021;122:105559.
    >> Share

    October 2021
  200. GEORGE A, Saseendran A, Joseph ST, Gopal KR, et al
    Submandibular gland - The victim of neck dissection.
    Oral Oncol. 2021;123:105591.
    >> Share

  201. CABEZAS-CAMARERO S, Alonso-Ovies A, Merino-Menendez S, Cabrera-Martin MN, et al
    Major pathological response and durable locoregional control after neoadjuvant pembrolizumab-carboplatin-paclitaxel in head and neck cancer.
    Oral Oncol. 2021;123:105589.
    >> Share

  202. BRUIJNEN CP, de Groot LGR, Vondeling AM, de Bree R, et al
    Functional decline after surgery in older patients with head and neck cancer.
    Oral Oncol. 2021;123:105584.
    >> Share

  203. PUTHIYOTTIL IV, Subash A, Thakur S, Rao VUS, et al
    Elective neck dissection versus sentinel node biopsy in early oral cavity cancer - Are we ready for transition?
    Oral Oncol. 2021;123:105597.
    >> Share

  204. SHINN JR, Carey RM, Mady LJ, Shimunov D, et al
    Sex-based differences in outcomes among surgically treated patients with HPV-related oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2021;123:105570.
    >> Share

  205. JOSE MARTELLI A, Assis Machado R, Medeiros Pereira W, Balduino Guimaraes Santos F, et al
    Revaluation of the treatment of head and neck cancer in Brazil during the COVID-19 pandemic - phase 2.
    Oral Oncol. 2021;123:105600.
    >> Share

  206. YUWANATI M, Sarode SC, Gadbail A, Gondivkar S, et al
    Alcohol attributed Oral Cancer and Oral microbiome: Emerging yet neglected research domain.
    Oral Oncol. 2021;123:105596.
    >> Share

  207. YU ST, Ge JN, Sun BH, Wei ZG, et al
    Lymph node yield in the initial central neck dissection (CND) associated with the risk of recurrence in papillary thyroid cancer: A reoperative CND cohort study.
    Oral Oncol. 2021;123:105567.
    >> Share

  208. SHU L, Wang D, Nannapaneni S, Sun Y, et al
    Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC).
    Oral Oncol. 2021;122:105546.
    >> Share

  209. MA D, Orner D, Ghaly MM, Parashar B, et al
    Automated health chats for symptom management of head and neck cancer patients undergoing radiation therapy.
    Oral Oncol. 2021;122:105551.
    >> Share

  210. ZHAO Y, Li WF, Li QJ, He SW, et al
    WIPI-1 inhibits metastasis and tumour growth via the WIPI-1-TRIM21 axis and MYC regulation in nasopharyngeal carcinoma.
    Oral Oncol. 2021;122:105576.
    >> Share

  211. ROSENBERG AJ, Agrawal N, Pearson A, Gooi Z, et al
    Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
    Oral Oncol. 2021;122:105566.
    >> Share

  212. TSENG WH, Li TH, Chiu HL, Yang TL, et al
    Long-term swallowing-related outcomes in oral cancer patients receiving proactive swallowing therapy.
    Oral Oncol. 2021;122:105569.
    >> Share

  213. BRIL SI, van Beers MA, Chargi N, Carrillo Minulina N, et al
    Skeletal muscle mass at C3 is a strong predictor for skeletal muscle mass at L3 in sarcopenic and non-sarcopenic patients with head and neck cancer.
    Oral Oncol. 2021;122:105558.
    >> Share

  214. PENG H, Chen L, Mao YP, Tian L, et al
    Nomogram-aided individual induction chemotherapy regimen selection in advanced nasopharyngeal carcinoma.
    Oral Oncol. 2021;122:105555.
    >> Share

  215. CARNEVALE C, Pagan-Pomar A, Bianchi A, Sarria-Echegaray P, et al
    Right colonic interposition for severe pharyngoesophageal stricture in head and neck patients: A feasible rescue strategy after multiple failed reconstructive options.
    Oral Oncol. 2021;121:105481.
    >> Share

  216. HANS S, Chebib E, Chekkoury-Idrissi Y, Distinguin L, et al
    Surgical and oncological outcomes of transoral robotic total laryngectomy: A case series.
    Oral Oncol. 2021;121:105511.
    >> Share

  217. FINEGERSH A, Voora RS, Panuganti B, Faraji F, et al
    Robotic surgery may improve overall survival for T1 and T2 tumors of the hypopharynx: An NCDB cohort study.
    Oral Oncol. 2021;121:105440.
    >> Share

  218. AL MASALMEH N, Kukreja G, Zaiem F, Raza SN, et al
    p16 positive oropharyngeal small cell cancer: A case report.
    Oral Oncol. 2021;121:105391.
    >> Share

  219. HARING CT, Brummel C, Bhambhani C, Jewell B, et al
    Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation.
    Oral Oncol. 2021;121:105332.
    >> Share

    September 2021
  220. CURY SS, Miranda PM, Marchi FA, Canto LMD, et al
    Germline variants in DNA repair genes are associated with young-onset head and neck cancer.
    Oral Oncol. 2021;122:105545.
    >> Share

  221. WANG BC
    Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Finding the suitable population.
    Oral Oncol. 2021 Sep 28:105544. doi: 10.1016/j.oraloncology.2021.105544.
    >> Share

  222. SARODE SC, Sarode GS, Sengupta N, Ghone U, et al
    Tobacco induced epithelial dysplasia at minor salivary gland excretory duct and oral cancer.
    Oral Oncol. 2021;122:105525.
    >> Share

  223. MENON N, Patil V, Noronha V, Joshi A, et al
    Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone - Additional data from a phase 3 trial.
    Oral Oncol. 2021;122:105517.
    >> Share

  224. ZHU MY, Sun XS, Guo SS, Chen QY, et al
    Do all patients with locoregionally advanced nasopharyngeal carcinoma benefit from the maintenance chemotherapy using S-1/capecitabine?
    Oral Oncol. 2021;122:105539.
    >> Share

  225. ZHOU X, Xu T, Yang Y, Xing X, et al
    Survival impact of increasing time to IMRT initiation following induction chemotherapy in nasopharyngeal carcinoma: A propensity score-matched analysis.
    Oral Oncol. 2021;122:105506.
    >> Share

  226. KIONG KL, Bell D, Yao CM, Ferrarotto R, et al
    Multifocal regression and pathologic response predicts recurrence after neoadjuvant chemotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2021;122:105520.
    >> Share

  227. AJAZ S, Muneer R, Siddiqa A, Ali Memon M, et al
    Association of specific single nucleotide variants (SNVs) in the promoter and 3'-Untranslated region of Vascular Endothelial growth factor (VEGF) gene with risk and higher tumour grade of head and neck cancers.
    Oral Oncol. 2021;122:105519.
    >> Share

  228. TSAI TY, Chou YC, Lu YA, Kang CJ, et al
    The prognostic value of radiologic extranodal extension in nasopharyngeal carcinoma: Systematic review and meta-analysis.
    Oral Oncol. 2021;122:105518.
    >> Share

  229. IDA S, Takahashi H, Kawabata-Iwakawa R, Mito I, et al
    Tissue-resident memory T cells correlate with the inflammatory tumor microenvironment and improved prognosis in head and neck squamous cell carcinoma.
    Oral Oncol. 2021;122:105508.
    >> Share

  230. SAKTHIVEL P, Malik A, Panda S, Dhiwakar M, et al
    8 "S" of obturators in Head and Neck Cancer Rehabilitation during COVID-19 pandemic.
    Oral Oncol. 2021 Sep 8:105523. doi: 10.1016/j.oraloncology.2021.105523.
    >> Share

  231. MILLIET F, Bozec A, Schiappa R, Viotti J, et al
    Metachronous second primary neoplasia in oropharyngeal cancer patients: Impact of tumor HPV status. A GETTEC multicentric study.
    Oral Oncol. 2021;122:105503.
    >> Share

  232. VAN HINTE G, Sancak T, Weijs WLJ, Merkx MAW, et al
    Effect of elective neck dissection versus sentinel lymph node biopsy on shoulder morbidity and health-related quality of life in patients with oral cavity cancer: A longitudinal comparative cohort study.
    Oral Oncol. 2021;122:105510.
    >> Share

    August 2021
  233. WRIGHT CM, Lee DY, Shimunov D, Carmona R, et al
    Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery.
    Oral Oncol. 2021;121:105509.
    >> Share

  234. VERDONCK-DE LEEUW IM, Melissant H, Lissenberg-Witte BI, Baatenburg de Jong RJ, et al
    Associations between testosterone and patient reported sexual outcomes among male and female head and neck cancer patients before and six months after treatment: A pilot study.
    Oral Oncol. 2021;121:105505.
    >> Share

  235. SCHAIK JEV, Halmos GB, Witjes MJH, Plaat BEC, et al
    An overview of the current clinical status of optical imaging in head and neck cancer with a focus on Narrow Band imaging and fluorescence optical imaging.
    Oral Oncol. 2021;121:105504.
    >> Share

  236. MYATRA SN, Gupta S, D'Cruz AK, Rajanala V, et al
    Identification of patients for a delayed extubation strategy versus elective tracheostomy for postoperative airway management in major oral cancer surgery: A prospective observational study in seven hundred and twenty patients.
    Oral Oncol. 2021;121:105502.
    >> Share

  237. MIN Y, Xiang K, Feng Y, Chen H, et al
    Development and validation of a population-based model for predicting the regional lymph node metastasis in adolescent differentiated thyroid carcinoma.
    Oral Oncol. 2021;121:105507.
    >> Share

  238. YANG Q, Xia L, Lin M, Zhang MX, et al
    The impact of induction chemotherapy on long-term quality of life in patients with locoregionally advanced nasopharyngeal carcinoma: Outcomes from a randomised phase 3 trial.
    Oral Oncol. 2021;121:105494.
    >> Share

  239. HOCHFELDER CG, Mehta V, Kabarriti R, McGinn AP, et al
    Survival analysis of patients with advanced hypopharyngeal cancer comparing patients who received primary surgery to those who received chemoradiation: An analysis of the NCDB.
    Oral Oncol. 2021;121:105470.
    >> Share

  240. BUENO DE OLIVEIRA T, Camila Braun A, Ribaldo Nicolau U, Ali Abdallah E, et al
    Prognostic impact and potential predictive role of baseline circulating tumor cells in locally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2021;121:105480.
    >> Share

  241. NAGPAL P, Pruthi DS, Pandey M, Yadav A, et al
    Impact of sarcopenia in locally advanced head and neck cancer treated with chemoradiation: An Indian tertiary care hospital experience.
    Oral Oncol. 2021;121:105483.
    >> Share

  242. JAWERT F, Nyman J, Olsson E, Adok C, et al
    Regular clinical follow-up of oral potentially malignant disorders results in improved survival for patients who develop oral cancer.
    Oral Oncol. 2021;121:105469.
    >> Share

  243. OHKOSHI A, Ishii R, Wakamori S, Nakayama Y, et al
    Serum selenium predicts achievement of full-dose cisplatin in concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: A prospective, observational study.
    Oral Oncol. 2021;121:105475.
    >> Share

  244. ENGEL MSD, van der Lans RJL, Jansen JC, Leemans CR, et al
    Management and outcome of middle ear adenomatous neuroendocrine tumours: A systematic review.
    Oral Oncol. 2021;121:105465.
    >> Share

  245. MCDOWELL L, Corry J
    Regarding "Comparing unilateral vs. bilateral neck management in lateralized oropharyngeal cancer between surgical and radiation oncologists: An international practice pattern survey" - Intra- and inter-specialty variability and the underutilisation o
    Oral Oncol. 2021;119:105248.
    >> Share

  246. CHOI N, Kim Z, Song BH, Park W, et al
    Prediction of risk factors for pharyngo-cutaneous fistula after total laryngectomy using artificial intelligence.
    Oral Oncol. 2021;119:105357.
    >> Share

    July 2021
  247. MAO L, Xiao Y, Yang QC, Yang SC, et al
    TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
    Oral Oncol. 2021;121:105472.
    >> Share

  248. NIEUWENHUIS ER, Kolenaar B, van Bemmel AJM, Hof JJ, et al
    A complete magnetic sentinel lymph node biopsy procedure in oral cancer patients: A pilot study.
    Oral Oncol. 2021;121:105464.
    >> Share

  249. MATSUDA Y, Okui T, Karino M, Aoi N, et al
    Postoperative oral dysfunction following oral cancer resection and reconstruction: A preliminary cross-sectional study.
    Oral Oncol. 2021;121:105468.
    >> Share

  250. NAUTA IH, Klausch T, van de Ven PM, Hoebers FJP, et al
    The important role of cisplatin in the treatment of HPV-positive oropharyngeal cancer assessed by real-world data analysis.
    Oral Oncol. 2021;121:105454.
    >> Share

  251. DRAKE V, Bigelow E, Fakhry C, Windon M, et al
    Biologic and behavioral associations of estrogen receptor alpha positivity in head and neck squamous cell carcinoma.
    Oral Oncol. 2021;121:105461.
    >> Share

  252. KIM C, Martinez E, Kulich M, Swanson MS, et al
    Surgeon practice patterns in transoral robotic surgery for HPV-related oropharyngeal cancer.
    Oral Oncol. 2021;121:105460.
    >> Share

  253. XU Y, Chen M, Guo Q, Peng H, et al
    Percutaneous endoscopic gastrostomy can improve survival outcomes in patients with N3 nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy.
    Oral Oncol. 2021;121:105435.
    >> Share

  254. ALMANGUSH A, Alabi RO, Makitie AA, Leivo I, et al
    Machine learning in head and neck cancer: Importance of a web-based prognostic tool for improved decision making.
    Oral Oncol. 2021 Jul 12:105452. doi: 10.1016/j.oraloncology.2021.105452.
    >> Share

  255. KOUKETSU A, Miyashita H, Kojima I, Sakamoto M, et al
    Comparison of different diagnostic imaging techniques for the detection of bone invasion in oral cancers.
    Oral Oncol. 2021;120:105453.
    >> Share

  256. MERCHANT YP, Kudpaje A, Rao VUS
    Extent of neck dissection in the N+ neck: Adjudicating a Conundrum!
    Oral Oncol. 2021 Jul 11:105441. doi: 10.1016/j.oraloncology.2021.105441.
    >> Share

  257. IQBAL MS, Kovarik J, Patil R, Kelly CG, et al
    Are taxanes more effective than 5FU in combination chemotherapy for recurrent and metastatic head and neck cancer?
    Oral Oncol. 2021 Jul 9:105455. doi: 10.1016/j.oraloncology.2021.105455.
    >> Share

  258. IMADUDDIN M, Sultania M, Vigneshwaran B, Muduly DK, et al
    Psychosocial Factors in an Oral Cancer Survivor Leading to Delay in Seeking Help.
    Oral Oncol. 2021 Jul 5:105438. doi: 10.1016/j.oraloncology.2021.105438.
    >> Share

  259. WILKIE MD, Lancaster J, Roland NJ, Jones TM, et al
    Elective management of regional nodal basins in cutaneous squamous cell carcinoma of the head and neck: Controversies and contemporary perspectives.
    Oral Oncol. 2021;120:105432.
    >> Share

  260. KIM SY, Beer M, Tshering Vogel DW
    Imaging in head and neck cancers: Update for non-radiologist.
    Oral Oncol. 2021;120:105434.
    >> Share

  261. FARLOW JL, Brenner JC, Lei YL, Chinn SB, et al
    Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
    Oral Oncol. 2021;120:105420.
    >> Share

  262. DA COSTA REAR, da Silva Junior RG, Magalhaes LAN, Mendes JR, et al
    Locally advanced lymphoepithelial carcinoma of the larynx/hypopharynx: A case report.
    Oral Oncol. 2021;118:105373.
    >> Share

  263. TURNER MT, Stokes WA, Stokes CM, Hassid S, et al
    Airway and bleeding complications of transoral robotic supraglottic laryngectomy (TORS-SGL): A systematic review and meta-analysis.
    Oral Oncol. 2021;118:105301.
    >> Share

  264. MCDOWELL L, Gough K, King M, Corry J, et al
    Patient-reported quality of life and symptom burden measures in human papillomavirus associated oropharyngeal cancer - A review of the literature and PRO methodology.
    Oral Oncol. 2021;118:105309.
    >> Share

  265. DHEERAJ K, Kumar R, Pinnaka LB
    6 "I" for endoscopic surgical management of early glottic squamous cell carcinomas.
    Oral Oncol. 2021;118:105308.
    >> Share

    June 2021
  266. PATEL KB, Mroz EA, Faquin WC, Rocco JW, et al
    A combination of intra-tumor genetic heterogeneity, estrogen receptor alpha and human papillomavirus status predicts outcomes in head and neck squamous cell carcinoma following chemoradiotherapy.
    Oral Oncol. 2021;120:105421.
    >> Share

  267. RIBEIRO IP, Lopes T, Pedro N, Barroso L, et al
    Should sitting time be a treatment target in head and neck cancer patients receiving curative treatment?
    Oral Oncol. 2021 Jun 26:105418. doi: 10.1016/j.oraloncology.2021.105418.
    >> Share

  268. DAHLSTROM KR, Anderson KS, Guo M, Kwon MC, et al
    Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial.
    Oral Oncol. 2021;120:105397.
    >> Share

  269. YANG J, Wan SQ, Huang L, Zhong WJ, et al
    Analysis of hospitalization costs and length of stay for oral cancer patients undergoing surgery: Evidence from Hunan, China.
    Oral Oncol. 2021;119:105363.
    >> Share

  270. AMBRE S, Sultania M, Biswal S, Mitra S, et al
    Poorly differentiated "insular" thyroid carcinoma with solitary vascular mandibular metastasis - A rare histology and management.
    Oral Oncol. 2021 Jun 24:105416. doi: 10.1016/j.oraloncology.2021.105416.
    >> Share

  271. ZHU MY, Wu HJ, Miao JJ, Di MP, et al
    Radiation-induced hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy with or without chemotherapy: Development of a nomogram based on the equivalent dose.
    Oral Oncol. 2021;120:105378.
    >> Share

  272. LENZE NR, Farquhar DR, Sheth S, Zevallos JP, et al
    Prognostic impact of socioeconomic status compared to overall stage for HPV-negative head and neck squamous cell carcinoma.
    Oral Oncol. 2021;119:105377.
    >> Share

  273. LIEN MY, Wang TH, Hsieh CY, Tsai MH, et al
    Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
    Oral Oncol. 2021;119:105380.
    >> Share

  274. KAVARTHAPU A, Gurumoorthy K
    Linking chronic periodontitis and oral cancer: A review.
    Oral Oncol. 2021 Jun 14:105375. doi: 10.1016/j.oraloncology.2021.105375.
    >> Share

  275. MA C, Sheng S, Shen Y, Gao W, et al
    A comparative study on using superior thyroid artery perforator flaps versus traditional sternocleidomastoid myocutaneous flaps for reconstructions after oral cancer ablation: "New tricks for old dogs"?
    Oral Oncol. 2021 Jun 11:105374. doi: 10.1016/j.oraloncology.2021.105374.
    >> Share

  276. BRAS L, de Vries J, Festen S, Steenbakkers RJHM, et al
    Frailty and restrictions in geriatric domains are associated with surgical complications but not with radiation-induced acute toxicity in head and neck cancer patients: A prospective study.
    Oral Oncol. 2021;118:105329.
    >> Share

  277. KARABAJAKIAN A, Bouaoud J, Michon L, Kamal M, et al
    Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity.
    Oral Oncol. 2021;119:105368.
    >> Share

  278. XU J, Wang R, Wang T, Wang T, et al
    Targeted DNA profiling and the prevalence of NTRK aberrations in Chinese patients with head and neck cancer.
    Oral Oncol. 2021;119:105369.
    >> Share

  279. JIANG WN, Olson R
    Transoral surgery may be less cost effective than radiotherapy: In response to: Comparative cost analysis between definitive radiotherapy and transoral surgery for oropharyngeal squamous cell carcinoma: A SEER-medicare analysis.
    Oral Oncol. 2021;117:105178.
    >> Share

  280. PARIKH AS, Kang SY
    Variation in elective treatment of the contralateral neck in oropharyngeal cancer.
    Oral Oncol. 2021;117:105186.
    >> Share

  281. COMBES JD, Voisin N, Perie S, Malard O, et al
    History of tonsillectomy and risk of oropharyngeal cancer.
    Oral Oncol. 2021;117:105302.
    >> Share

  282. JANSEN F, Coupe VMH, Eerenstein SEJ, Cnossen IC, et al
    Cost-utility and cost-effectiveness of a guided self-help head and neck exercise program for patients treated with total laryngectomy: Results of a multi-center randomized controlled trial.
    Oral Oncol. 2021;117:105306.
    >> Share

  283. PATEL MR, Ottenstein L, Ryan M, Farrell A, et al
    TORS elective lingual tonsillectomy has less acute morbidity than therapeutic base of tongue TORS.
    Oral Oncol. 2021;117:105294.
    >> Share

    May 2021
  284. TECKIE S, Wotman M, Marziliano A, Orner D, et al
    Patterns of alcohol use among early head and neck cancer survivors: A cross-sectional survey study using the alcohol use disorders identification test (AUDIT).
    Oral Oncol. 2021;119:105328.
    >> Share

  285. DE FELICE F, Lei M, Oakley R, Lyons A, et al
    Risk stratified follow up for head and neck cancer patients - An evidence based proposal.
    Oral Oncol. 2021;119:105365.
    >> Share

  286. LIN MC, Leu YS, Chiang CJ, Ko JY, et al
    Adequate surgical margins for oral cancer: A Taiwan cancer registry national database analysis.
    Oral Oncol. 2021;119:105358.
    >> Share

  287. PENG Y, Xiao L, Rong H, Ou Z, et al
    Single-cell profiling of tumor-infiltrating TCF1/TCF7(+) T cells reveals a T lymphocyte subset associated with tertiary lymphoid structures/organs and a superior prognosis in oral cancer.
    Oral Oncol. 2021;119:105348.
    >> Share

  288. COSTANTINO A, De Virgilio A, Spriano G
    Is the current oropharyngeal cancer T classification adequate in the era of HPV and transoral robotic surgery?
    Oral Oncol. 2021 May 25:105359. doi: 10.1016/j.oraloncology.2021.105359.
    >> Share

  289. DESIDERI I, Becherini C, Belgioia L, Merlotti A, et al
    Palliative radiotherapy in older adults with head and neck squamous cell carcinoma: A systematic review.
    Oral Oncol. 2021;119:105355.
    >> Share

  290. BERZENJI D, Sewnaik A, Keereweer S, Monserez DA, et al
    Dissemination patterns and chronology of distant metastasis affect survival of patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2021;119:105356.
    >> Share

  291. SCHOONBEEK RC, Bult FFS, Plaat BEC, Witjes MJH, et al
    Incidental findings during the diagnostic work-up in the head and neck cancer pathway: Effects on treatment delay and survival.
    Oral Oncol. 2021;118:105350.
    >> Share

  292. CHEN X, Li Y, Li X, Cao X, et al
    An interpretable machine learning prognostic system for locoregionally advanced nasopharyngeal carcinoma based on tumor burden features.
    Oral Oncol. 2021;118:105335.
    >> Share

  293. PATTERSON JM, Lu L, Watson LJ, Harding S, et al
    Trends in, and predictors of, swallowing and social eating outcomes in head and neck cancer survivors: A longitudinal analysis of head and neck 5000.
    Oral Oncol. 2021;118:105344.
    >> Share

  294. AL-QURAYSHI Z, Randolph GW, Kandil E
    Cost-effectiveness of computed tomography nodal scan in patients with papillary thyroid carcinoma.
    Oral Oncol. 2021;118:105326.
    >> Share

  295. VENTURA TMO, Santos PSS, Ribeiro NR, de Lima Leite A, et al
    Is there difference in the comparative and quantitative salivary proteome between stimulated and unstimulated saliva in head and neck cancer patients treated by radiotherapy?
    Oral Oncol. 2021 May 10:105315. doi: 10.1016/j.oraloncology.2021.105315.
    >> Share

  296. ZHOU L
    Concerns about human papillomavirus-associated oropharyngeal cancer detection methods.
    Oral Oncol. 2021;116:105143.
    >> Share

  297. LI R, Wang Q, Yan L, Zhu Y, et al
    Radiotherapy versus partial laryngectomy in the management of early glottic cancer with anterior commissure involvement: A propensity score matched study with 256 patients.
    Oral Oncol. 2021;116:105230.
    >> Share

    April 2021
  298. DA SILVA LEONEL ACL, Ribeiro ILA, de Souza MLM, Kaminagakura E, et al
    COVID-19, changes in smoking behaviour, and head and neck cancer: Current data and future perspectives.
    Oral Oncol. 2021 Apr 30:105327. doi: 10.1016/j.oraloncology.2021.105327.
    >> Share

  299. ZONG J, Liu Y, Liang Q, Xu H, et al
    Administration of oral maintenance chemotherapy for 1 year following definitive chemoradiotherapy may improve the survival of patients with stage N3 nasopharyngeal carcinoma.
    Oral Oncol. 2021;118:105313.
    >> Share

  300. SINHA NK, Kohli PS, Nagarajan K, Gochhait D, et al
    A nomogram for predicting the risk of neck node metastasis in oral cavity carcinoma using acoustic radiation force impulse imaging (ARFI).
    Oral Oncol. 2021;118:105311.
    >> Share

  301. CHEN JL, Wang Q, Huang LM, Xu YH, et al
    A rare case of Kimura disease with lumps on the cheek and behind the ear.
    Oral Oncol. 2021 Apr 28:105303. doi: 10.1016/j.oraloncology.2021.105303.
    >> Share

  302. YVER CM, Shimunov D, Weinstein GS, Rajasekaran K, et al
    Oncologic and survival outcomes for resectable locally-advanced HPV-related oropharyngeal cancer treated with transoral robotic surgery.
    Oral Oncol. 2021;118:105307.
    >> Share

  303. LYNCH PT, Horani S, Lee R, Sumer BD, et al
    Effectiveness of physical activity interventions in improving objective and patient-reported outcomes in head and neck cancer survivors: A systematic review.
    Oral Oncol. 2021;117:105253.
    >> Share

  304. VALLINA C, Lopez-Pintor RM, Gonzalez-Serrano J, de Vicente JC, et al
    Genes involved in the epithelial-mesenchymal transition in oral cancer: A systematic review.
    Oral Oncol. 2021;117:105310.
    >> Share

  305. RAJASEKARAN K, Carey RM, Lin X, Seckar TD, et al
    The microbiome of HPV-positive tonsil squamous cell carcinoma and neck metastasis.
    Oral Oncol. 2021;117:105305.
    >> Share

  306. KREINBRINK PJ, Li J, Parajuli S, Wise-Draper TM, et al
    Pre-treatment absolute lymphocyte count predicts for improved survival in human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2021;116:105245.
    >> Share

  307. DHAKAL R, Moeller BJ, Prabhu RS, Frenkel CH, et al
    Pattern of distant metastasis in oropharyngeal carcinoma - Do they differ by HPV status?
    Oral Oncol. 2021 Apr 18:105286. doi: 10.1016/j.oraloncology.2021.105286.
    >> Share

  308. FANNY C, Sebastien L, Pascale G, Antoine N, et al
    Physician practice variation in head and neck cancer therapy: Results of a national survey.
    Oral Oncol. 2021;117:105293.
    >> Share

  309. MOUTAFI M, Economopoulou P, Rimm D, Psyrri A, et al
    PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
    Oral Oncol. 2021;117:105292.
    >> Share

  310. XIANG ZF, Hu DF, Xiong HC, Li MY, et al
    Benefit of chemotherapy in stage III nasopharyngeal carcinoma: Analysis of the surveillance, epidemiology, and end results database.
    Oral Oncol. 2021;117:105284.
    >> Share

  311. KUMAR R, Dheeraj K
    Do ipsilateral lateralized squamous cell carcinomas of oral tongue with a depth of invasion (DOI) greater than 10 mm warrant a bilateral neck dissection to prevent future regional recurrences on contralateral side? A continuing conundrum.
    Oral Oncol. 2021 Apr 7:105285. doi: 10.1016/j.oraloncology.2021.105285.
    >> Share

  312. SCHREIBER A, Mattavelli D, Accorona R, Rampinelli V, et al
    Endoscopic-assisted multi-portal compartmental resection of the masticatory space in oral cancer: Anatomical study and preliminary clinical experience.
    Oral Oncol. 2021;117:105269.
    >> Share

  313. SAKTHIVEL P, Raveendran S, Panda S, Singh CA, et al
    Synchronous primary neoplasia in patients with p16 positive oropharyngeal carcinoma: Does the 2nd cancer really matters?
    Oral Oncol. 2021;115:105113.
    >> Share

  314. PRICE JM, West CM, Mistry HB, Betts G, et al
    Improved survival prediction for oropharyngeal cancer beyond TNMv8.
    Oral Oncol. 2021;115:105140.
    >> Share

    March 2021
  315. SWAIN M, Ghosh-Laskar S
    Stereotactic body radiotherapy (SBRT) for primary non-metastatic head and neck cancer: When less is enough.
    Oral Oncol. 2021;116:105265.
    >> Share

  316. IQBAL MS, Morgan D, West N, Paterson C, et al
    Hypofractionated chemoradiation (2.75 Gy per fraction) in Head and Neck Cancer: Extreme caution required.
    Oral Oncol. 2021 Mar 21:105261. doi: 10.1016/j.oraloncology.2021.105261.
    >> Share

  317. CAO C, Gan X, He Y, Su Y, et al
    Diagnostic efficacy of PET-CT, CT, and MRI in preoperative assessment of mandibular invasion caused by head and neck cancer: A systematic review and meta-analysis.
    Oral Oncol. 2021;116:105264.
    >> Share

  318. PUCCI R, Cassoni A, Battisti A, Valentini V, et al
    Covid-19 pandemic and head and neck cancers, what should we expect?
    Oral Oncol. 2021 Mar 15:105263. doi: 10.1016/j.oraloncology.2021.105263.
    >> Share

  319. TANI R, Ito N, Matsui K, Yamasaki S, et al
    MICA A5.1 homozygous genotype is associated with a risk for early-onset oral cancer.
    Oral Oncol. 2021;116:105256.
    >> Share

  320. DIANA G, Corica C
    Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence?
    Oral Oncol. 2021;115:105168.
    >> Share

  321. KIM HAJ, Zeng PYF, Shaikh MH, Mundi N, et al
    All HPV-negative head and neck cancers are not the same: Analysis of the TCGA dataset reveals that anatomical sites have distinct mutation, transcriptome, hypoxia, and tumor microenvironment profiles.
    Oral Oncol. 2021;116:105260.
    >> Share

  322. ILHAN B, Guneri P, Wilder-Smith P
    The contribution of artificial intelligence to reducing the diagnostic delay in oral cancer.
    Oral Oncol. 2021;116:105254.
    >> Share

  323. MO Y, Zhang B, Pan Y, Qin Q, et al
    Impact of the weekday of the first intensity-modulated radiotherapy treatment on the survival outcomes of patients with nasopharyngeal carcinoma: A multicenter cohort study.
    Oral Oncol. 2021;116:105258.
    >> Share

  324. LAN R, Catherine JH, Chossegros C, Campana F, et al
    Temporal association between the introduction of public health programs and interest in oral cancers on the internet in the European Union.
    Oral Oncol. 2021 Mar 5:105250. doi: 10.1016/j.oraloncology.2021.105250.
    >> Share

  325. CHUMPITAZ-CERRATE V, Chavez-Rimache L, Rodriguez-Flores A
    Challenges in the early diagnosis of oral cancer in rural populations in Peru during the COVID-19 pandemic.
    Oral Oncol. 2021 Mar 1:105251. doi: 10.1016/j.oraloncology.2021.105251.
    >> Share

  326. DE ALMEIDA JR, Seungyeon Kim V, O'Sullivan B, Goldstein DP, et al
    Comparing unilateral vs. bilateral neck management in lateralized oropharyngeal cancer between surgical and radiation oncologists: An international practice pattern survey.
    Oral Oncol. 2021;114:105165.
    >> Share

  327. FERRARI M, Migliorati S, Tomasoni M, Crisafulli V, et al
    Sinonasal cancer encroaching the orbit: Ablation or preservation?
    Oral Oncol. 2021;114:105185.
    >> Share

  328. YANG K, Ahn YC, Nam H, Hong SD, et al
    Clinical features of post-radiation nasopharyngeal necrosis and their outcomes following surgical intervention in nasopharyngeal cancer patients.
    Oral Oncol. 2021;114:105180.
    >> Share

  329. HENG Y, Zhang D, Zhou L, Zhang M, et al
    Assessment and treatment strategies for occult contralateral lymph node metastasis in hypopharyngeal squamous cell carcinoma patients with ipsilateral node-positive necks.
    Oral Oncol. 2021;114:105183.
    >> Share

  330. CUI J, Wang D, Nie D, Liu W, et al
    Difference in tumor mutation burden between squamous cell carcinoma in the oral cavity and larynx.
    Oral Oncol. 2021;114:105142.
    >> Share

  331. OPPELT P, Ley JC, Worden F, Palka K, et al
    Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial.
    Oral Oncol. 2021;114:105164.
    >> Share

  332. GOOSMANN M, Chang S, Craig J
    Treating sinonasal crusting and infection after palatal and sinonasal cancer resection with topical antibiotic irrigations.
    Oral Oncol. 2021;114:105077.
    >> Share

    February 2021
  333. AWAN MJ, Gittleman H, Barnholtz-Sloan J, Machtay M, et al
    Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522.
    Oral Oncol. 2021;116:105241.
    >> Share

  334. DEVARAJA K
    Erratum to "The surgical sequence of neck dissection and primary tumor excision could impact the locoregional recurrence rates in oral squamous cell carcinoma" [Oral Oncol. 110 (2020) 104809].
    Oral Oncol. 2021 Feb 24:105229. doi: 10.1016/j.oraloncology.2021.105229.
    >> Share

  335. ZSCHAECK S, Weingartner J, Ghadjar P, Wust P, et al
    Fever range whole body hyperthermia for re-irradiation of head and neck squamous cell carcinomas: Final results of a prospective study.
    Oral Oncol. 2021;116:105240.
    >> Share

  336. LIN M, Yang Q, You R, Zou X, et al
    Metastatic characteristics associated with survival of synchronous metastatic nasopharyngeal carcinoma in non-epidemic areas.
    Oral Oncol. 2021;115:105200.
    >> Share

  337. NORTH LM, Harvey E, Vanle B, Shreenivas A, et al
    Frequent omission of radiation after flap reconstruction of head and neck cancer: Are we dooming patients to failure?
    Oral Oncol. 2021 Feb 18:105225. doi: 10.1016/j.oraloncology.2021.105225.
    >> Share

  338. HUANG L, Zhang X, Bai Y, Chua KLM, et al
    Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study.
    Oral Oncol. 2021;115:105222.
    >> Share

  339. FADEN DL, O'Boyle CJ, Lin DT, Deschler DG, et al
    Prospective assessment of multiple HPV-positive oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2021 Feb 15:105212. doi: 10.1016/j.oraloncology.2021.105212.
    >> Share

  340. SANTOSO AMM, Jansen F, Lissenberg-Witte BI, Baatenburg de Jong RJ, et al
    Sleep quality trajectories from head and neck cancer diagnosis to six months after treatment.
    Oral Oncol. 2021;115:105211.
    >> Share

  341. LEON X, Orus C, Casasayas M, Neumann E, et al
    Trends in disease-specific survival of head and neck squamous cell carcinoma patients treated in a single institution over a 30-year period.
    Oral Oncol. 2021;115:105184.
    >> Share

  342. GALLO O, Locatello LG
    All that glitters is not gold: Clinical implications from the genetic analysis of head and neck cancer recurrences.
    Oral Oncol. 2021 Feb 10:105187. doi: 10.1016/j.oraloncology.2021.105187.
    >> Share

  343. MA SJ, Iovoli AJ, Attwood K, Wooten KE, et al
    Association of significant financial burden with survival for head and neck cancer patients treated with radiation therapy.
    Oral Oncol. 2021;115:105196.
    >> Share

  344. ADKINS DR, Lin JC, Sacco A, Ley J, et al
    Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naive, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial.
    Oral Oncol. 2021;115:105192.
    >> Share

  345. MENEZES FDS, Fernandes GA, Antunes JLF, Villa LL, et al
    Global incidence trends in head and neck cancer for HPV-related and -unrelated subsites: A systematic review of population-based studies.
    Oral Oncol. 2021;115:105177.
    >> Share

  346. VIGANO A, De Felice F, Iacovelli NA, Alterio D, et al
    M. D. Anderson symptom inventory head neck (MDASI-HN) questionnaire: Italian language psychometric validation in head and neck cancer patients treated with radiotherapy +/- systemic therapy - A study of the Italian Association of Radiotherapy and Clin
    Oral Oncol. 2021;115:105189.
    >> Share

  347. OH LJ, Satgunaseelan L, Asher R, Veness M, et al
    Young age is not a predictor of disease specific survival in oral cancer: A multi-institutional study.
    Oral Oncol. 2021;115:105162.
    >> Share

  348. ADKINS D, Ley J, Atiq O, Powell S, et al
    Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial.
    Oral Oncol. 2021;115:105173.
    >> Share

  349. LEE SJ, Kim YS, Kay CS, Kim M, et al
    The effect of adjuvant chemotherapy and early tumor regression on the outcome of nasopharyngeal cancer patients treated with concurrent chemoradiotherapy.
    Oral Oncol. 2021;113:105130.
    >> Share

  350. CARNEVALE C, Ortiz-Gonzalez I, Ortiz-Gonzalez A, Bodi-Blanes L, et al
    Early T1-T2 stage p16+ oropharyngeal tumours. Role of upfront transoral robotic surgery in de-escalation treatment strategies. A review of the current literature.
    Oral Oncol. 2021;113:105111.
    >> Share

  351. HEFT NEAL ME, Gao RW, Brennan JR, Haring CT, et al
    Functional outcomes and tracheostomy dependence following salvage oropharyngeal surgery.
    Oral Oncol. 2021;113:105034.
    >> Share

    January 2021
  352. THADURI A, Chadha L, Poonia DR, Rajkumar KS, et al
    Oral cancer screening - A delphic horizon in India.
    Oral Oncol. 2021 Jan 26:105174. doi: 10.1016/j.oraloncology.2020.105174.
    >> Share

  353. MA HH, Chen DS, Li S, Xiao MZ, et al
    The value and inadequacy of tumor mutation burden on efficacy of immune checkpoint inhibitors in head and neck cancers.
    Oral Oncol. 2021 Jan 26:105179. doi: 10.1016/j.oraloncology.2021.105179.
    >> Share

  354. JELINEK MJ, Foster NR, Zoroufy AJ, Schwartz GK, et al
    A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.
    Oral Oncol. 2021;114:105171.
    >> Share

  355. CHAN SK, Chan SY, Tong CC, Lam KO, et al
    Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carc
    Oral Oncol. 2021;114:105158.
    >> Share

  356. PILAR A, Yu E, Su J, O'Sullivan B, et al
    Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma.
    Oral Oncol. 2021;114:105167.
    >> Share

  357. HOWLETT J, Hamilton S, Ye A, Jewett D, et al
    Treatment and outcomes of nasopharyngeal carcinoma in a unique non-endemic population.
    Oral Oncol. 2021;114:105182.
    >> Share

  358. MARTELLI AJ, Machado RA, Pereira WM, Silveira DMM, et al
    Impact of the COVID-19 pandemic in the head and neck cancer treatment in the Brazil.
    Oral Oncol. 2021 Jan 18:105148. doi: 10.1016/j.oraloncology.2020.105148.
    >> Share

  359. DEVARAJA K
    De-escalation of aggressive adjuvant therapy for limited extranodal extension in head and neck cancer.
    Oral Oncol. 2021 Jan 18:105161. doi: 10.1016/j.oraloncology.2020.105161.
    >> Share

  360. BHATTASALI O, Torres FA, Kang HK, Thompson LDR, et al
    Prognostic impact of retropharyngeal lymphadenopathy in early-stage HPV-associated oropharyngeal cancer: Implications for staging optimization.
    Oral Oncol. 2021;114:105147.
    >> Share

  361. VARELA-CENTELLES P, Seoane J, Bilbao A, Seoane-Romero J, et al
    Covid-19 pandemic: A new contributing factor to diagnostic and treatment delay in oral cancer patients.
    Oral Oncol. 2021 Jan 15:105176. doi: 10.1016/j.oraloncology.2020.105176.
    >> Share

  362. JOHNSON D, Ma BBY
    Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma.
    Oral Oncol. 2021;113:105127.
    >> Share

  363. TREVISIOL C, Gion M, Vaona A, Fabricio ASC, et al
    The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: Comprehensive clinical practice guidelines evaluation.
    Oral Oncol. 2021;114:105128.
    >> Share

  364. EMMETT SE, Stark MS, Pandeya N, Panizza B, et al
    MicroRNA expression is associated with human papillomavirus status and prognosis in mucosal head and neck squamous cell carcinomas.
    Oral Oncol. 2021;113:105136.
    >> Share

  365. SHER DJ, Yan J, Day AT, Khan S, et al
    Comparative cost analysis between definitive radiotherapy and transoral surgery for oropharyngeal squamous cell carcinoma: A SEER-Medicare analysis.
    Oral Oncol. 2021;112:105029.
    >> Share

  366. WINDON MJ, Le D, D'Souza G, Bigelow E, et al
    Treatment decision-making among patients with oropharyngeal squamous cell cancer: A qualitative study.
    Oral Oncol. 2021;112:105044.
    >> Share

  367. FLUKES S, Lohia S, Barker CA, Cracchiolo JR, et al
    Are our patients doing better? A single institution experience of an evolving management paradigm for sinonasal mucosal melanoma.
    Oral Oncol. 2021;112:105006.
    >> Share

    December 2020
  368. LORINI L, Merlano M, Licitra L, Ravanelli M, et al
    Brain metastasis in head and neck squamous cell carcinoma after immune check point inhibitors treatment.
    Oral Oncol. 2020 Dec 31:105138. doi: 10.1016/j.oraloncology.2020.105138.
    >> Share

  369. VIPPARTHI K, Patel AK, Ghosh S, Das S, et al
    Two novel cell culture models of buccal mucosal oral cancer from patients with no risk-habits of tobacco smoking or chewing.
    Oral Oncol. 2020;113:105131.
    >> Share

  370. PELLINI R, Campo F, Sergi D, Cappuzzo F, et al
    Role of Pembrolizumab in recurrent or metastatic head and neck carcinoma.
    Oral Oncol. 2020 Dec 29:105133. doi: 10.1016/j.oraloncology.2020.105133.
    >> Share

  371. ALMANGUSH A, Makitie AA, Leivo I
    Back to basics: Hematoxylin and eosin staining is the principal tool for histopathological risk assessment of oral cancer.
    Oral Oncol. 2020 Dec 29:105134. doi: 10.1016/j.oraloncology.2020.105134.
    >> Share

  372. MATSUO M, Yasumatsu R, Masuda M, Toh S, et al
    Drug-induced interstitial lung disease in recurrent and/or metastatic head and neck cancer patients treated with cetuximab and/or nivolumab.
    Oral Oncol. 2020;113:105129.
    >> Share

  373. CHRISTOPHERSON KM, Moreno AC, Elgohari B, Gross N, et al
    Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation.
    Oral Oncol. 2020;113:105125.
    >> Share

  374. SUBRAMANIAM N, Clark JR, Goldstein D, de Almeida J, et al
    Geographical heterogeneity in the American Joint committee on Cancer oral cancer staging and prognostic implications.
    Oral Oncol. 2020;113:105122.
    >> Share

  375. NOEL CW, Sutradhar R, Li Q, Forner D, et al
    Chinese and South Asian ethnicity, immigration status and head and neck cancer outcomes: A population based study.
    Oral Oncol. 2020;113:105118.
    >> Share

    November 2020
  376. KOBAYASHI K, Yoshimoto S, Ando M, Matsumoto F, et al
    Full-coverage TP53 deep sequencing of recurrent head and neck squamous cell carcinoma facilitates prognostic assessment after recurrence.
    Oral Oncol. 2020;113:105091.
    >> Share

  377. MAZUL AL, Naik AN, Zhan KY, Stepan KO, et al
    Gender and race interact to influence survival disparities in head and neck cancer.
    Oral Oncol. 2020;112:105093.
    >> Share

  378. MASHIANA SS, Navale P, Khandakar B, Sobotka S, et al
    Human papillomavirus genotype distribution in head and neck cancer: Informing developing strategies for cancer prevention, diagnosis, treatment and surveillance.
    Oral Oncol. 2020;113:105109.
    >> Share

  379. ROY D, Patel A, Goswami G, Samantaray S, et al
    Role of Onco rehabilitation in head and neck cancer.
    Oral Oncol. 2020 Nov 19:105015. doi: 10.1016/j.oraloncology.2020.105015.
    >> Share

  380. KHAN SA, Burke M, Zhu F, Yang DH, et al
    Survivin expression and impact on head and neck cancer outcomes.
    Oral Oncol. 2020;112:105049.
    >> Share

  381. ZHAO XT, Zhu Y, Zhou JF, Gao YJ, et al
    Development of a novel 7 immune-related genes prognostic model for oral cancer: A study based on TCGA database.
    Oral Oncol. 2020;112:105088.
    >> Share

  382. CHAKRABARTI D, Akhtar N, Qayoom S, Rajan S, et al
    Optimising elective neck dissection for early oral cancers.
    Oral Oncol. 2020 Nov 13:105090. doi: 10.1016/j.oraloncology.2020.105090.
    >> Share

  383. WIJETUNGA NA, Yu Y, Morris LG, Lee N, et al
    The head and neck cancer genome in the era of immunotherapy.
    Oral Oncol. 2020;112:105040.
    >> Share

  384. ZHAI TT, Wesseling F, Langendijk JA, Shi Z, et al
    External validation of nodal failure prediction models including radiomics in head and neck cancer.
    Oral Oncol. 2020;112:105083.
    >> Share

  385. REGO-LORCA D, Burgos-Blasco B, Hernandez-Garcia E, Domingo-Gordo B, et al
    Abducens palsy as first manifestation of a nasopharyngeal carcinoma.
    Oral Oncol. 2020 Nov 10:105079. doi: 10.1016/j.oraloncology.2020.105079.
    >> Share

  386. LIU AK, Wu J, Berthelet E, Lalani N, et al
    Clinical features of head and neck cancer patients with brain metastases: A retrospective study of 88 cases.
    Oral Oncol. 2020;112:105086.
    >> Share

  387. CHO JH, Lim YC
    Prognostic impact of regulatory T cell in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2020;112:105084.
    >> Share

  388. HANNA GJ, Rettig EM, Park JC, Varvares MA, et al
    Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19.
    Oral Oncol. 2020;112:105087.
    >> Share

  389. AMPIL F, Cuellar H, Nathan CA, Smith D, et al
    Recurrent head and neck cancers in the skull base, stereotactic radiosurgery palliation, and risk prognosticators.
    Oral Oncol. 2020 Nov 3:105005. doi: 10.1016/j.oraloncology.2020.105005.
    >> Share

  390. SAKTHIVEL P, Samy K, Panda S, Amit Singh C, et al
    14 "S" in head and neck cancers.
    Oral Oncol. 2020;112:105070.
    >> Share

    October 2020
  391. AMPIL FL, Nathan CA, Asarkar A
    Long-term survival in patients with intermediate-risk head and neck cancer treated with adjuvant radiotherapy.
    Oral Oncol. 2020 Oct 30:105071. doi: 10.1016/j.oraloncology.2020.105071.
    >> Share

  392. PANDOLFINI M, Di Stadio A, Brenner MJ, Pichi B, et al
    Airway obstruction from tracheostomy balloon cuff herniation during oral cancer asportation. Emergency successfully managed and lessons learnt from device malfunction.
    Oral Oncol. 2020 Oct 29:105048. doi: 10.1016/j.oraloncology.2020.105048.
    >> Share

  393. SAIDAK Z, Galmiche A, Lottin M, Montes L, et al
    The coagulome of Head and Neck Squamous Cell Carcinoma.
    Oral Oncol. 2020 Oct 28:105068. doi: 10.1016/j.oraloncology.2020.105068.
    >> Share

  394. FLEMING CW, Ward MC, Woody NM, Joshi NP, et al
    Identifying an oligometastatic phenotype in HPV-associated oropharyngeal squamous cell cancer: Implications for clinical trial design.
    Oral Oncol. 2020;112:105046.
    >> Share

  395. MILLIET F, Bozec A, Schiappa R, Viotti J, et al
    Synchronous primary neoplasia in patients with oropharyngeal cancer: Impact of tumor HPV status. A GETTEC multicentric study.
    Oral Oncol. 2020;112:105041.
    >> Share

  396. IMADUDDIN M, Sultania M, Vigneshwaran B, Muduly DK, et al
    Metronomic therapy using Methotrexate and Celecoxib: A Boon for Oral Cancer patients during COVID-19 Pandemic.
    Oral Oncol. 2020 Oct 24:105069. doi: 10.1016/j.oraloncology.2020.105069.
    >> Share

  397. MORIKAWA T, Shibahara T, Takano M, Iwamoto M, et al
    Countermeasure and opportunistic screening systems for oral cancer.
    Oral Oncol. 2020;112:105047.
    >> Share

  398. GUPTA T, Ghosh-Laskar S, Agarwal JP
    Resource-sparing curative-intent hypofractionated-accelerated radiotherapy in head and neck cancer: More relevant than ever before in the COVID era.
    Oral Oncol. 2020;111:105045.
    >> Share

  399. LEK SM, Li K, Tan QX, Shannon NB, et al
    Pairing a prognostic target with potential therapeutic strategy for head and neck cancer.
    Oral Oncol. 2020;111:105035.
    >> Share

  400. FERRARI M, Paderno A, Giannini L, Cazzador D, et al
    COVID-19 screening protocols for preoperative assessment of head and neck cancer patients candidate for elective surgery in the midst of the pandemic: A narrative review with comparison between two Italian institutions.
    Oral Oncol. 2020;112:105043.
    >> Share

  401. PARK JC, Durbeck J, Clark JR, Faden DL, et al
    Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes.
    Oral Oncol. 2020;111:105024.
    >> Share

  402. DE VRIES J, Bras L, Sidorenkov G, Festen S, et al
    Frailty is associated with decline in health-related quality of life of patients treated for head and neck cancer.
    Oral Oncol. 2020;111:105020.
    >> Share

  403. CONTRERA KJ, Smile TD, Mahomva C, Wei W, et al
    Locoregional and distant recurrence for HPV-associated oropharyngeal cancer using AJCC 8 staging.
    Oral Oncol. 2020;111:105030.
    >> Share

  404. HUANG S, Piao Y, Cao C, Chen J, et al
    A prospective randomized controlled trial on the value of prophylactic oral nutritional supplementation in locally advanced nasopharyngeal carcinoma patients receiving chemo-radiotherapy.
    Oral Oncol. 2020;111:105025.
    >> Share

  405. SUBRAMANIAM N, Dhar SK, Rao R, Prasad K, et al
    Novel tyrosine metabolites in the transcriptomic profiling of smokeless tobacco related oral cancer and their potential implications.
    Oral Oncol. 2020 Oct 1:105027. doi: 10.1016/j.oraloncology.2020.105027.
    >> Share

  406. CUSTODIO M, Biddle A, Tavassoli M
    Portrait of a CAF: The story of cancer-associated fibroblasts in head and neck cancer.
    Oral Oncol. 2020;110:104972.
    >> Share

    September 2020
  407. CHOW JCH, Tam AHP, Cheung KM, Lee VHF, et al
    Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSG.
    Oral Oncol. 2020;111:105012.
    >> Share

  408. ECONOMOPOULOU P, Kotsantis I, Papaxoinis G, Gavrielatou N, et al
    Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
    Oral Oncol. 2020;111:105013.
    >> Share

  409. RAPADO-GONZALEZ O, Muinelo-Romay L, Suarez-Cunqueiro MM
    Letter to the editor: "Liquid biopsy based on saliva cell-free DNA as a potential biomarker for head and neck cancer".
    Oral Oncol. 2020 Sep 21:105016. doi: 10.1016/j.oraloncology.2020.105016.
    >> Share

  410. YETE S, Saranath D
    MicroRNAs in oral cancer: Biomarkers with clinical potential.
    Oral Oncol. 2020;110:105002.
    >> Share

  411. MARTIN M, Sautois B
    Early onset of head and neck squamous-cell carcinoma and fatal toxicity with concurrent chemoradiotherapy in a patient compound heterozygote for FANCA gene.
    Oral Oncol. 2020 Sep 1:104989. doi: 10.1016/j.oraloncology.2020.104989.
    >> Share

    August 2020
  412. FAKHRY C, Fung N, Tewari SR, D'Souza G, et al
    Unique role of HPV16 in predicting oropharyngeal cancer risk more than other oncogenic oral HPV infections.
    Oral Oncol. 2020 Aug 29:104981. doi: 10.1016/j.oraloncology.2020.104981.
    >> Share

  413. CHEN TC, Wu CT, Wang CP, Lou PJ, et al
    The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
    Oral Oncol. 2020;111:104945.
    >> Share

  414. WANG J, Lian CL, Zheng H, Lin LE, et al
    Cognitive dysfunction in patients with nasopharyngeal carcinoma after induction chemotherapy.
    Oral Oncol. 2020;111:104921.
    >> Share

  415. DENARO N, Merlotti AM, Merlano MC, Russi E, et al
    Coronavirus disease 19 (COVID-19) during chemoradiation for locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).
    Oral Oncol. 2020;107:104801.
    >> Share

    July 2020
  416. ZENG YY, Xiang ZZ, He T, Liu F, et al
    The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2020;111:104924.
    >> Share

  417. WANG Q, Xu G, Xia Y, Zuo J, et al
    Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2020;111:104925.
    >> Share

  418. LI W, Lu H, Liu J, Liu Q, et al
    A novel nomogram to predict survival in patients with recurrent nasopharyngeal carcinoma after salvage endoscopic surgery.
    Oral Oncol. 2020;111:104922.
    >> Share

  419. HSU AC, Kokot NC, Eisenberg BL, Thomas JS, et al
    Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report.
    Oral Oncol. 2020 Jul 11:104899. doi: 10.1016/j.oraloncology.2020.104899.
    >> Share

  420. MATOS LL, Pinheiro RA, Kowalski LP
    Depth of invasion applied to oropharynx does not improve prognosis discrimination according to AJCC stage groups for oral cancer.
    Oral Oncol. 2020 Jul 9:104890. doi: 10.1016/j.oraloncology.2020.104890.
    >> Share

  421. BRCIC I, Gallob M, Schwantzer G, Zrnc T, et al
    Concordance of tumor infiltrating lymphocytes, PD-L1 and p16 expression in small biopsies, resection and lymph node metastases of oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;106:104719.
    >> Share

  422. COHEN ER, Reis IM, Gomez-Fernandez C, Smith D, et al
    CD44 and associated markers in oral rinses and tissues from oral and oropharyngeal cancer patients.
    Oral Oncol. 2020;106:104720.
    >> Share

  423. KISHIMOTO Y, Tateya I, Funakoshi M, Miyamoto SI, et al
    Endoscopic laryngopharyngeal surgery for hypopharyngeal lesions.
    Oral Oncol. 2020;106:104655.
    >> Share

  424. SEKARUTAMI SM, Gondhowiardjo S, Yuliasti R, Syarifah L, et al
    Survival of nasopharyngeal cancer in national referral hospital of Indonesia: A study on radiotherapy patients.
    Oral Oncol. 2020;106:104707.
    >> Share

  425. FERRARI M, Ioppi A, Schreiber A, Gualtieri T, et al
    Malignant tumors of the maxillary sinus: Prognostic impact of neurovascular invasion in a series of 138 patients.
    Oral Oncol. 2020;106:104672.
    >> Share

    June 2020
  426. KREIMER AR, Chaturvedi AK, Alemany L, Anantharaman D, et al
    Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI.
    Oral Oncol. 2020;108:104736.
    >> Share

  427. IQBAL MS, Warner L, Paleri V, Kovarik J, et al
    De-intensification of treatment in human papilloma virus related oropharyngeal carcinoma: Patient choice still matters for de-escalation and for the COVID era.
    Oral Oncol. 2020;105:104768.
    >> Share

  428. SASAKI CT, Hajek M, Doukas SG, Vageli DP, et al
    The role of bile reflux and its related NF-kappaB activated pathway in progression of hypopharyngeal squamous cell cancer.
    Oral Oncol. 2020;105:104668.
    >> Share

  429. BIGELOW EO, Seiwert TY, Fakhry C
    Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions.
    Oral Oncol. 2020;105:104652.
    >> Share

  430. JANK BJ, Kadletz L, Dunkler D, Haas M, et al
    Epithelial stem cell marker LGR6 expression identifies a low-risk subgroup in human papillomavirus positive oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;105:104657.
    >> Share

    May 2020
  431. JOO YH, Cho KJ, Kim GJ, Kim MS, et al
    Prognostic impact of resection margin involvement in surgically managed HPV-positive tonsil cancer.
    Oral Oncol. 2020;108:104806.
    >> Share

  432. KYLMA AK, Jouhi L, Mohamed H, Randen-Brady R, et al
    In HPV-negative oropharyngeal squamous cell carcinoma, elevated toll-like receptor 2 immunoexpression may increase the risk of disease-specific mortality.
    Oral Oncol. 2020;107:104778.
    >> Share

  433. MANNELLI G, Gazzini L, Comini LV, Parrinello G, et al
    Double free flaps in oral cavity and oropharynx reconstruction: Systematic review, indications and limits.
    Oral Oncol. 2020;104:104637.
    >> Share

  434. CHOW VLY, Chan JYW, Cheng IKY, Chan KMK, et al
    Swallowing disorders following free jejunal flap reconstruction of circumferential pharyngeal defect: Does Botox help?
    Oral Oncol. 2020;104:104612.
    >> Share

    April 2020
  435. MOLONY P, Werner R, Martin C, Callanan D, et al
    The role of tumour morphology in assigning HPV status in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;105:104670.
    >> Share

  436. PATEL RR, Ludmir EB, Augustyn A, Zaorsky NG, et al
    De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials.
    Oral Oncol. 2020;103:104608.
    >> Share

  437. DE VIRGILIO A, Costantino A, Mercante G, Di Maio P, et al
    Trans-oral robotic surgery in the management of parapharyngeal space tumors: A systematic review.
    Oral Oncol. 2020;103:104581.
    >> Share

  438. CANAVAN JF, Harr BA, Bodmann JW, Reddy CA, et al
    Impact of routine surveillance imaging on detecting recurrence in human papillomavirus associated oropharyngeal cancer.
    Oral Oncol. 2020;103:104585.
    >> Share

  439. FARLOW JL, Rosko AJ, Spector ME
    Treatment of end-stage pharyngeal strictures after laryngectomy with fasciocutaneous microvascular reconstruction.
    Oral Oncol. 2020;103:104556.
    >> Share

  440. CABEZAS-CAMARERO S, Perez-Alfayate R, Puebla F, Cabrera-Martin MN, et al
    Increased clinical and plasma EBV DNA responses to platinum-gemcitabine after nivolumab in patients with heavily platinum-pretreated nasopharyngeal cancer.
    Oral Oncol. 2020;103:104527.
    >> Share

    March 2020
  441. MAZUL AL, Colditz GA, Zevallos JP
    Factors associated with HPV testing in oropharyngeal cancer in the National Cancer Data Base from 2013 to 2015.
    Oral Oncol. 2020;104:104609.
    >> Share

  442. SANDULACHE VC, Lei YL, Heasley LE, Chang M, et al
    Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting.
    Oral Oncol. 2020;102:104440.
    >> Share

    February 2020
  443. YIN X, Shan C, Wang J, Zhang H, et al
    Factors associated with the quality of life for hospitalized patients with HPV-associated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;103:104590.
    >> Share

  444. FAKHRY C, Waterboer T, Westra WH, Rooper LM, et al
    Distinct biomarker and behavioral profiles of human papillomavirus-related oropharynx cancer patients by age.
    Oral Oncol. 2020;101:104522.
    >> Share

  445. WANG Z, Qu Y, Wang K, Wu R, et al
    The value of preoperative radiotherapy in the treatment of locally advanced nasal cavity and paranasal sinus squamous cell carcinoma: A single institutional experience.
    Oral Oncol. 2020;101:104512.
    >> Share

  446. CHARGI N, Bril SI, Swartz JE, Wegner I, et al
    Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;101:104519.
    >> Share

  447. SATO K, Ono T, Sato F, Kawahara A, et al
    Different responses to nivolumab therapy between primary and metastatic tumors in a patient with recurrent hypopharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;101:104366.
    >> Share

    December 2019
  448. YOUNG RJ, Bressel M, Porceddu S, Cernelc J, et al
    Validation and characterisation of prognostically significant PD-L1(+) immune cells in HPV+ oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2019;101:104516.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016